	title	geo_accession	status	submission_date	last_update_date	type	channel_count	source_name_ch1	organism_ch1	characteristics_ch1	characteristics_ch1.1	characteristics_ch1.2	characteristics_ch1.3	characteristics_ch1.4	characteristics_ch1.5	characteristics_ch1.6	characteristics_ch1.7	characteristics_ch1.8	characteristics_ch1.9	characteristics_ch1.10	characteristics_ch1.11	characteristics_ch1.12	characteristics_ch1.13	characteristics_ch1.14	characteristics_ch1.15	characteristics_ch1.16	characteristics_ch1.17	characteristics_ch1.18	characteristics_ch1.19	characteristics_ch1.20	characteristics_ch1.21	characteristics_ch1.22	characteristics_ch1.23	characteristics_ch1.24	treatment_protocol_ch1	growth_protocol_ch1	molecule_ch1	extract_protocol_ch1	label_ch1	label_protocol_ch1	taxid_ch1	hyb_protocol	scan_protocol	description	data_processing	platform_id	contact_name	contact_email	contact_department	contact_institute	contact_address	contact_city	contact_state	contact_zip/postal_code	contact_country	supplementary_file	data_row_count	relation	age:ch1	array qc:ch1	biopsy date mmddyy:ch1	bmn grade:ch1	dlda30 pred (1=pcr, 0=rd):ch1	dlda30 score:ch1	er status:ch1	er% positive:ch1	her 2 fish:ch1	her 2 ihc:ch1	her 2 status:ch1	histology:ch1	pcr or rd:ch1	post chemo +ln/total:ch1	post chemo size cm:ch1	pr status:ch1	pr% positive:ch1	prechemo n:ch1	prechemo t:ch1	preoperative treatment:ch1	race:ch1	randomized (1=fac, 2=t/fac):ch1	surgery date:ch1	surgery type:ch1	treatment received (1=fac, 2=t/fac):ch1
GSM508012	breast cancer SPAIN28	GSM508012	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 29.0801979318585	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 11-11-05	age: 48	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 2	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: FEC x(6 )	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Lumpectomy	surgery date: 5-16-06	post chemo size cm: 0	post chemo +ln/total: 0/12	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508012/suppl/GSM508012_FL850-Spain28.CEL.gz	22283	Reanalyzed by: GSE205568	48	Pass	11-11-05	3	1	29.0801979318585	N	0	ND	0	N	Infiltrating Ductal Carcinoma	pCR	0/12	0	N	0	2	2	FEC x(6 )	W	1	5-16-06	Lumpectomy	1
GSM508013	breast cancer SPAIN58	GSM508013	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -0.0128475189085293	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-4-06	age: 55	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 3	prechemo n: 0	bmn grade: 2	er% positive: 3+	er status: P	pr% positive: 2+	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: ND	preoperative treatment: FEC x(6 )	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Lumpectomy	surgery date: 9-9-06	post chemo size cm: 1.2	post chemo +ln/total: 1/10	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508013/suppl/GSM508013_FL743-Spain58.CEL.gz	22283	Reanalyzed by: GSE205568	55	Pass	11-4-06	2	0	-0.0128475189085293	P	3+	ND	1	N	Infiltrating Ductal Carcinoma	RD	1/10	1.2	P	2+	0	3	FEC x(6 )	W	1	9-9-06	Lumpectomy	1
GSM508014	breast cancer SPAIN36	GSM508014	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -3.66978477240264	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-30-06	age: 45	race: W	histology: infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: ND	preoperative treatment: FEC x(6 )	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Lumpectomy	surgery date: 6-26-06	post chemo size cm: 2.1	post chemo +ln/total: 0/24	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508014/suppl/GSM508014_FL1288_GM36.CEL.gz	22283	Reanalyzed by: GSE205568	45	Pass	1-30-06	3	0	-3.66978477240264	N	0	ND	3	P	infiltrating Ductal Carcinoma	RD	0/24	2.1	N	0	0	2	FEC x(6 )	W	1	6-26-06	Lumpectomy	1
GSM508015	breast cancer SPAIN30	GSM508015	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -24.1551184509099	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 2-1-06	age: 39	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 2	bmn grade: 2	er% positive: 2+	er status: P	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: FEC x(6 )	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Mastectomy	surgery date: 5-24-06	post chemo size cm: 0.3	post chemo +ln/total: 1/13	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508015/suppl/GSM508015_FL739-Spain30.CEL.gz	22283	Reanalyzed by: GSE205568	39	Pass	2-1-06	2	0	-24.1551184509099	P	2+	ND	0	N	Infiltrating Ductal Carcinoma	RD	1/13	0.3	N	0	2	2	FEC x(6 )	W	1	5-24-06	Mastectomy	1
GSM508016	breast cancer SPAIN44	GSM508016	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -33.6082225731752	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 2-13-06	age: 49	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 1	prechemo n: 0	bmn grade: 1	er% positive: 25-50	er status: P	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 1	her 2 fish: ND	preoperative treatment: FEC x(6 )	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Mastectomy	surgery date: 7-27-06	post chemo size cm: 1	post chemo +ln/total: 0/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508016/suppl/GSM508016_FL1306_GM44.CEL.gz	22283	Reanalyzed by: GSE205568	49	Pass	2-13-06	1	0	-33.6082225731752	P	25-50	ND	1	N	Infiltrating Ductal Carcinoma	RD	0/18	1	N	0	0	1	FEC x(6 )	W	1	7-27-06	Mastectomy	1
GSM508017	breast cancer SPAIN50	GSM508017	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 5.84682794709261	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 2-13-06	age: 39	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 3	prechemo n: 1	bmn grade: 2	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: positive	preoperative treatment: FEC x(6 )	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Mastectomy	surgery date: 7-26-06	post chemo size cm: 2	post chemo +ln/total: 0/13	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508017/suppl/GSM508017_FL1404_GM50.CEL.gz	22283	Reanalyzed by: GSE205568	39	Pass	2-13-06	2	1	5.84682794709261	N	0	positive	3	P	Infiltrating Ductal Carcinoma	RD	0/13	2	N	0	1	3	FEC x(6 )	W	1	7-26-06	Mastectomy	1
GSM508018	breast cancer SPAIN31	GSM508018	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -10.2109884376205	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 12-20-05	age: 48	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: N/A	prechemo n: 1	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 75	pr status: P	her 2 status: P	her 2 ihc: 3	her 2 fish: ND	preoperative treatment: FECx(6)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Mastectomy	surgery date: 5-24-06	post chemo size cm: 2.3	post chemo +ln/total: 1/10	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508018/suppl/GSM508018_Fl851_2_-Spain31.CEL.gz	22283	Reanalyzed by: GSE205568	48	Pass	12-20-05	3	0	-10.2109884376205	N	0	ND	3	P	Infiltrating Ductal Carcinoma	RD	1/10	2.3	P	75	1	N/A	FECx(6)	W	1	5-24-06	Mastectomy	1
GSM508019	breast cancer SPAIN11	GSM508019	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -4.12028377736351	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-23-05	age: 73	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 3	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 60	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: FEC x(6 )	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Mastectomy	surgery date: 2-20-06	post chemo size cm: 3.4	post chemo +ln/total: 1/16	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508019/suppl/GSM508019_FL737-spain11.CEL.gz	22283	Reanalyzed by: GSE205568	73	Pass	9-23-05	3	0	-4.12028377736351	N	0	ND	0	N	Infiltrating Ductal Carcinoma	RD	1/16	3.4	P	60	0	3	FEC x(6 )	W	1	2-20-06	Mastectomy	1
GSM508020	breast cancer SPAIN32	GSM508020	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -20.3249113937945	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-13-06	age: 42	race: W	histology: infiltrating Mucosecretor Carcinoma	prechemo t: 3	prechemo n: 1	bmn grade: 2	er% positive: 100	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: FEC x(5 ) due to NC +Paclitaxel x (7)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Mastectomy	surgery date: 6-19-06	post chemo size cm: 4	post chemo +ln/total: 2/7	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508020/suppl/GSM508020_FL1287_GM32.CEL.gz	22283	Reanalyzed by: GSE205568	42	Pass	1-13-06	2	0	-20.3249113937945	P	100	ND	0	N	infiltrating Mucosecretor Carcinoma	RD	2/7	4	P	90	1	3	FEC x(5 ) due to NC +Paclitaxel x (7)	W	1	6-19-06	Mastectomy	1
GSM508021	breast cancer SPAIN49	GSM508021	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -33.998468130947	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 2-16-06	age: 42	race: H	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 1	bmn grade: 3	er% positive: 75	er status: P	pr% positive: 99	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: ND	preoperative treatment: FEC x(6 )	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Mastectomy	surgery date: 7-21-06	post chemo size cm: 8	post chemo +ln/total: 11/14	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508021/suppl/GSM508021_FL741-Spain49.CEL.gz	22283	Reanalyzed by: GSE205568	42	Pass	2-16-06	3	0	-33.998468130947	P	75	ND	1	N	Infiltrating Ductal Carcinoma	RD	11/14	8	P	99	1	2	FEC x(6 )	H	1	7-21-06	Mastectomy	1
GSM508022	breast cancer SPAIN21	GSM508022	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -27.6535301342938	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 6-4-06	age: 45	race: W	histology: Infiltrating Lobular Carcinoma	prechemo t: 3	prechemo n: 1	bmn grade: 3	er% positive: 2+	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: FEC x(6 )	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Mastectomy	surgery date: 6-4-06	post chemo size cm: 8	post chemo +ln/total: 3/15	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508022/suppl/GSM508022_FL992-Spain21.CEL.gz	22283	Reanalyzed by: GSE205568	45	Pass	6-4-06	3	0	-27.6535301342938	N	2+	ND	0	N	Infiltrating Lobular Carcinoma	RD	3/15	8	N	0	1	3	FEC x(6 )	W	1	6-4-06	Mastectomy	1
GSM508023	breast cancer SPAIN42	GSM508023	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -34.3341992550595	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 2-27-06	age: 62	race: W	histology: Mixed; Ductal and Lobular	prechemo t: 3	prechemo n: 0	bmn grade: 2	er% positive: 100	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: FEC x( 6)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Mastectomy	surgery date: 7-31-06	post chemo size cm: Not medible	post chemo +ln/total: 5/12	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508023/suppl/GSM508023_FL1305_GM42.CEL.gz	22283	Reanalyzed by: GSE205568	62	Pass	2-27-06	2	0	-34.3341992550595	P	100	ND	0	N	Mixed; Ductal and Lobular	RD	5/12	Not medible	P	90	0	3	FEC x( 6)	W	1	7-31-06	Mastectomy	1
GSM508024	breast cancer PERU16-18	GSM508024	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -17.3934742990386	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 2-2-05	age: 46	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: N/A	er% positive: 90	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC  x 6  (Taxol x 12 post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 7-26-05	post chemo size cm: 1	post chemo +ln/total: 4/25	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508024/suppl/GSM508024_29539_AB01723007_35647.CEL.gz	22283	Reanalyzed by: GSE205568	46	Pass	2-2-05	N/A	0	-17.3934742990386	P	90	N/A	N/A	N	IDC	RD	4/25	1	P	90	1	4	FAC  x 6  (Taxol x 12 post Sx)	H	1	7-26-05	MRM	1
GSM508025	breast cancer 713	GSM508025	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -22.7706989769194	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 3-15-06	age: 50	race: W	histology: IDC	prechemo t: 1	prechemo n: 1	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.1	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 9-8-06	post chemo size cm: 1.5	post chemo +ln/total: 6/9	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508025/suppl/GSM508025_FL454-713.CEL.gz	22283	Reanalyzed by: GSE205568	50	Pass	3-15-06	3	0	-22.7706989769194	N	0	1.1	N/A	N	IDC	RD	6/9	1.5	N	0	1	1	FEC x 6	W	1	9-8-06	MRM	1
GSM508026	breast cancer 400	GSM508026	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -19.5015532606067	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 4-2-04	age: 55	race: W	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 2	er% positive: 50	er status: P	pr% positive: 10	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: 0	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 10-7-04	post chemo size cm: 2	post chemo +ln/total: 8/43	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508026/suppl/GSM508026_U133A_FL47_400_07_12_05.CEL.gz	22283	Reanalyzed by: GSE205568	55	Pass	4-2-04	2	0	-19.5015532606067	P	50	0	N/A	N	IDC	RD	8/43	2	P	10	1	2	FEC x 6	W	1	10-7-04	MRM	1
GSM508027	breast cancer 725	GSM508027	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -40.6774191149871	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 4-11-06	age: 46	race: W	histology: IDC	prechemo t: 2	prechemo n: 3	bmn grade: 1	er% positive: 91	er status: P	pr% positive: 100	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: 1.25	preoperative treatment: FEC x 6 (P.D “new supra & infraclavicular Ln”)Taxol x 12	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 12-8-06	post chemo size cm: 2	post chemo +ln/total: 6/13	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508027/suppl/GSM508027_FL683-725.CEL.gz	22283	Reanalyzed by: GSE205568	46	Pass	4-11-06	1	0	-40.6774191149871	P	91	1.25	1	N	IDC	RD	6/13	2	P	100	3	2	FEC x 6 (P.D “new supra & infraclavicular Ln”)Taxol x 12	W	1	12-8-06	MRM	1
GSM508028	breast cancer 338	GSM508028	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -34.5040635264359	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-19-03	age: 45	race: W	histology: IDC	prechemo t: 1	prechemo n: 1	bmn grade: 1	er% positive: 95	er status: P	pr% positive: 80	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: 1.65	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 5-26-04	post chemo size cm: 3	post chemo +ln/total: 3/11	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508028/suppl/GSM508028_U133A_FL59-338_07_27_05.CEL.gz	22283	Reanalyzed by: GSE205568	45	Pass	11-19-03	1	0	-34.5040635264359	P	95	1.65	1	N	IDC	RD	3/11	3	P	80	1	1	FEC x 6	W	1	5-26-04	MRM	1
GSM508029	breast cancer 439	GSM508029	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -4.86178614556411	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 7-27-04	age: 73	race: W	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: 10.81	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 12-16-04	post chemo size cm: 3.3	post chemo +ln/total: 0/16	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508029/suppl/GSM508029_U133A_FL60-439_07_28_05.CEL.gz	22283	Reanalyzed by: GSE205568	73	Pass	7-27-04	3	0	-4.86178614556411	N	0	10.81	3	P	IDC	RD	0/16	3.3	N	0	0	2	FEC x 6	W	1	12-16-04	MRM	1
GSM508030	breast cancer 378	GSM508030	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -14.6217073369044	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 2-20-04	age: 50	race: W	histology: IDC	prechemo t: 4	prechemo n: 0	bmn grade: 2	er% positive: 50	er status: P	pr% positive: 50	pr status: P	her 2 status: N	her 2 ihc: 2	her 2 fish: 1.66	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 8-17-04	post chemo size cm: 3.5	post chemo +ln/total: 10/12	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508030/suppl/GSM508030_U133A_FL40-378_07_07_05.CEL.gz	22283	Reanalyzed by: GSE205568	50	Pass	2-20-04	2	0	-14.6217073369044	P	50	1.66	2	N	IDC	RD	10/12	3.5	P	50	0	4	FAC x 6	W	1	8-17-04	MRM	1
GSM508031	breast cancer 380	GSM508031	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -14.4342277970845	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 3-30-04	age: 50	race: W	histology: IDC	prechemo t: 2	prechemo n: 3	bmn grade: 2	er% positive: 100	er status: P	pr% positive: 20	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.08	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 9-16-04	post chemo size cm: 3.8	post chemo +ln/total: 7/17	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508031/suppl/GSM508031_U133A_FL41-380_07_07_05.CEL.gz	22283	Reanalyzed by: GSE205568	50	Pass	3-30-04	2	0	-14.4342277970845	P	100	1.08	N/A	N	IDC	RD	7/17	3.8	P	20	3	2	FEC x 6	W	1	9-16-04	MRM	1
GSM508032	breast cancer 466	GSM508032	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -14.2849270347415	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-3-04	age: 64	race: W	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 80	er status: P	pr% positive: 10	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.02	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 2-16-05	post chemo size cm: 4	post chemo +ln/total: 10/31	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508032/suppl/GSM508032_U133A_FL63-466_07_28_05.CEL.gz	22283	Reanalyzed by: GSE205568	64	Pass	9-3-04	2	0	-14.2849270347415	P	80	1.02	N/A	N	IDC	RD	10/31	4	P	10	0	2	FAC x 6	W	1	2-16-05	MRM	1
GSM508033	breast cancer PERU13-15	GSM508033	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -5.53218911083059	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-21-05	age: 43	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: N/A	er% positive: 75	er status: P	pr% positive: 70	pr status: P	her 2 status: N	her 2 ihc: 2	her 2 fish: N/A	preoperative treatment: FAC  x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 8-20-05	post chemo size cm: residual cancer	post chemo +ln/total: 0/5	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508033/suppl/GSM508033_U133A_80_FL_086_FL262-PERU13_04_20_06.CEL.gz	22283	Reanalyzed by: GSE205568	43	Pass	1-21-05	N/A	0	-5.53218911083059	P	75	N/A	2	N	IDC	RD	0/5	residual cancer	P	70	1	4	FAC  x 6	H	1	8-20-05	MRM	1
GSM508034	breast cancer PERU25	GSM508034	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 1.17038336382939	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 7-13-05	age: 43	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: 3	er% positive: 70	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: N/A	preoperative treatment: FAC  x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 1-28-06	post chemo size cm: residual cancer	post chemo +ln/total: 0/0		N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508034/suppl/GSM508034_FL399-PERU25.CEL.gz	22283	Reanalyzed by: GSE205568	43	Pass	7-13-05	3	1	1.17038336382939	P	70	NA	N/A	N	IDC	RD	0/0	residual cancer	P	90	1	4	FAC  x 6	H	1	1-28-06	MRM	1
GSM508035	breast cancer LBJ038	GSM508035	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: -1.98709040028552	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-8-04	age: 58	race: H	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 2	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FAC x 6 Taxol x 4	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 4-1-05	post chemo size cm: 0	post chemo +ln/total: 0/14	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508035/suppl/GSM508035_FL432-LBJ38.CEL.gz	22283	Reanalyzed by: GSE205568	58	Pass	9-8-04	2	0	-1.98709040028552	N	0	N/A	0	N	IDC	pCR	0/14	0	N	0	1	2	FAC x 6 Taxol x 4	H	1	4-1-05	MRM/ALND	1
GSM508036	breast cancer PERU36	GSM508036	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: -24.2596317393072	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-16-05	age: 43	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: N/A	er% positive: 90	er status: P	pr% positive: 5	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 3-7-06	post chemo size cm: 0	post chemo +ln/total: 0/8	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508036/suppl/GSM508036_FL414-PERU36.CEL.gz	22283	Reanalyzed by: GSE205568	43	Pass	9-16-05	N/A	0	-24.2596317393072	P	90	N/A	N/A	N	IDC	pCR	0/8	0	N	5	2	4	FAC x 6  (Taxol post Sx)	H	1	3-7-06	MRM/ALND	1
GSM508037	breast cancer PERU50	GSM508037	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: -21.5988509010549	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-30-05	age: 44	race: H	histology: IDC	prechemo t: 2	prechemo n: 2	bmn grade: N/A	er% positive: 95	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 6-6-06	post chemo size cm: 0	post chemo +ln/total: 0/14	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508037/suppl/GSM508037_FL418-PERU50.CEL.gz	22283	Reanalyzed by: GSE205568	44	Pass	11-30-05	N/A	0	-21.5988509010549	P	95	N/A	N/A	N	IDC	pCR	0/14	0	P	90	2	2	FAC x 6  (Taxol post Sx)	H	1	6-6-06	MRM/ALND	1
GSM508038	breast cancer PERU41	GSM508038	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: -26.0478919497036	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-23-05	age: 46	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: N/A	er% positive: 30	er status: P	pr% positive: 30	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 3-21-06	post chemo size cm: 0	post chemo +ln/total: 0/6	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508038/suppl/GSM508038_FL413-PERU41.CEL.gz	22283	Reanalyzed by: GSE205568	46	Pass	9-23-05	N/A	0	-26.0478919497036	P	30	N/A	N/A	N	IDC	pCR	0/6	0	P	30	2	4	FAC x 6	H	1	3-21-06	MRM/ALND	1
GSM508039	breast cancer 631	GSM508039	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -27.3757086879777	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 8-30-05	age: 32	race: W	histology: IDC	prechemo t: 2	prechemo n: 2	bmn grade: 3	er% positive: 90	er status: P	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FAC x 6 (Last Cycle only AC  no 5-FU)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 2-2-06	post chemo size cm: 1	post chemo +ln/total: 0/36	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508039/suppl/GSM508039_U133A_80-FL-217-FL381-631_09_08_06.CEL.gz	22283	Reanalyzed by: GSE205568	32	Pass	8-30-05	3	0	-27.3757086879777	P	90	N/A	0	N	IDC	RD	0/36	1	N	0	2	2	FAC x 6 (Last Cycle only AC  no 5-FU)	W	1	2-2-06	MRM/ALND	1
GSM508040	breast cancer 595	GSM508040	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -9.08304162674358	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 5-13-05	age: 54	race: W	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: 2	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: 4.7	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 2-20-06	post chemo size cm: 1.9	post chemo +ln/total: 27/28	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508040/suppl/GSM508040_U133A_80-FL-214-FL378-595_09_01_06.CEL.gz	22283	Reanalyzed by: GSE205568	54	Pass	5-13-05	2	0	-9.08304162674358	N	0	4.7	3	P	IDC	RD	27/28	1.9	N	0	2	4	FEC x 6	W	1	2-20-06	MRM/ALND	1
GSM508041	breast cancer 539	GSM508041	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 8.80421884619864	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 1-13-05	age: 66	race: W	histology: IDC/ILC	prechemo t: 1	prechemo n: 1	bmn grade: 2	er% positive: 40	er status: P	pr% positive: 5	pr status: N	her 2 status: N	her 2 ihc: 1	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 7-27-05	post chemo size cm: 2.3	post chemo +ln/total: 25/34		N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508041/suppl/GSM508041_FL446-539.CEL.gz	22283	Reanalyzed by: GSE205568	66	Pass	1-13-05	2	1	8.80421884619864	P	40	NA	1	N	IDC/ILC	RD	25/34	2.3	N	5	1	1	FAC x 6	W	1	7-27-05	MRM/ALND	1
GSM508042	breast cancer LBJ016	GSM508042	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 16.5271190224721	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 5-5-04	age: 39	race: H	histology: IDC	prechemo t: 3	prechemo n: 2	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol  x  6  FAC x  6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 11-12-04	post chemo size cm: 2.3	post chemo +ln/total: 0/10	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508042/suppl/GSM508042_U133A_FL66-LBJ16_08_04_05.CEL.gz	22283	Reanalyzed by: GSE205568	39	Pass	5-5-04	3	1	16.5271190224721	N	0	N/A	0	N	IDC	RD	0/10	2.3	N	0	2	3	Taxol  x  6  FAC x  6	H	1	11-12-04	MRM/ALND	1
GSM508043	breast cancer 572	GSM508043	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 18.5109907498372	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 4-12-05	age: 58	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.04	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 11-2-05	post chemo size cm: 5	post chemo +ln/total: 9/16	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508043/suppl/GSM508043_U133A_80-FL-213-FL377-572_09_01_06.CEL.gz	22283	Reanalyzed by: GSE205568	58	Pass	4-12-05	3	1	18.5109907498372	N	0	1.04	N/A	N	IDC	RD	9/16	5	N	0	2	4	FEC x 6	H	1	11-2-05	MRM/ALND	1
GSM508044	breast cancer PERU38	GSM508044	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -30.3483060718263	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-23-05	age: 52	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: 2	er% positive: 60	er status: P	pr% positive: 70	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol x 12 post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 3-16-06	post chemo size cm: N/A	post chemo +ln/total: 5/9	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508044/suppl/GSM508044_FL415-PERU38.CEL.gz	22283	Reanalyzed by: GSE205568	52	Pass	9-23-05	2	0	-30.3483060718263	P	60	N/A	N/A	N	IDC	RD	5/9	N/A	P	70	1	4	FAC x 6  (Taxol x 12 post Sx)	H	1	3-16-06	MRM/ALND	1
GSM508045	breast cancer PERU73	GSM508045	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -15.6391525074705	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 4-3-06	age: 61	race: H	histology: IDC	prechemo t: 3	prechemo n: 2	bmn grade: 3	er% positive: 100	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 11-21-06	post chemo size cm: N/A	post chemo +ln/total: 15/20	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508045/suppl/GSM508045_FL466-PERU73.CEL.gz	22283	Reanalyzed by: GSE205568	61	Pass	4-3-06	3	0	-15.6391525074705	P	100	N/A	1	N	IDC	RD	15/20	N/A	P	90	2	3	FAC x 6  (Taxol post Sx)	H	1	11-21-06	MRM/ALND	1
GSM508046	breast cancer PERU72	GSM508046	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -4.74275371467775	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 4-24-06	age: 37	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: 3	er% positive: 70	er status: P	pr% positive: 100	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol x 12 post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 10-28-06	post chemo size cm: N/A	post chemo +ln/total: 6/23	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508046/suppl/GSM508046_FL465-PERU72.CEL.gz	22283	Reanalyzed by: GSE205568	37	Pass	4-24-06	3	0	-4.74275371467775	P	70	N/A	N/A	N	IDC	RD	6/23	N/A	P	100	2	4	FAC x 6  (Taxol x 12 post Sx)	H	1	10-28-06	MRM/ALND	1
GSM508047	breast cancer PERU44	GSM508047	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -4.24123639165373	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 10-12-05	age: 40	race: H	histology: IDC	prechemo t: 4	prechemo n: 0	bmn grade: 3	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol x 11 post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 4-11-06	post chemo size cm: N/A	post chemo +ln/total: 3/11	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508047/suppl/GSM508047_U133A_80-FL-228-FL392-PERU44_09_29_06.CEL.gz	22283	Reanalyzed by: GSE205568	40	Pass	10-12-05	3	0	-4.24123639165373	N	N/A	N/A	N/A	N	IDC	RD	3/11	N/A	N	N/A	0	4	FAC x 6  (Taxol x 11 post Sx)	H	1	4-11-06	MRM/ALND	1
GSM508048	breast cancer PERU57	GSM508048	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -14.3196718975942	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-4-06	age: 41	race: H	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 1	er% positive: 90	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 7-8-06	post chemo size cm: N/A	post chemo +ln/total: 6/19	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508048/suppl/GSM508048_FL425-PERU57.CEL.gz	22283	Reanalyzed by: GSE205568	41	Pass	1-4-06	1	0	-14.3196718975942	P	90	N/A	N/A	N	IDC	RD	6/19	N/A	P	90	1	2	FAC x 6  (Taxol post Sx)	H	1	7-8-06	MRM/ALND	1
GSM508049	breast cancer PERU55	GSM508049	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -0.976595169557186	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 12-14-05	age: 42	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: 3	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol x 12 post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 5-27-06	post chemo size cm: N/A	post chemo +ln/total: 8/12	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508049/suppl/GSM508049_FL472-PERU55.CEL.gz	22283	Reanalyzed by: GSE205568	42	Pass	12-14-05	3	0	-0.976595169557186	N	N/A	N/A	N/A	N	IDC	RD	8/12	N/A	N	N/A	1	4	FAC x 6  (Taxol x 12 post Sx)	H	1	5-27-06	MRM/ALND	1
GSM508050	breast cancer PERU69	GSM508050	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -27.988309142087	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 3-29-06	age: 53	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: 2	er% positive: 70	er status: P	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol x 12 post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 10-12-06	post chemo size cm: N/A	post chemo +ln/total: 1/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508050/suppl/GSM508050_FL427-PERU69.CEL.gz	22283	Reanalyzed by: GSE205568	53	Pass	3-29-06	2	0	-27.988309142087	P	70	N/A	N/A	N	IDC	RD	1/18	N/A	N	N/A	2	4	FAC x 6  (Taxol x 12 post Sx)	H	1	10-12-06	MRM/ALND	1
GSM508051	breast cancer PERU27	GSM508051	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -44.4286101111029	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 8-3-05	age: 62	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: 3	er% positive: 100	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC  x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 1-26-06	post chemo size cm: residual cancer	post chemo +ln/total: 0/17	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508051/suppl/GSM508051_U133A_80-FL-227-FL391-PERU27_09_29_06.CEL.gz	22283	Reanalyzed by: GSE205568	62	Pass	8-3-05	3	0	-44.4286101111029	P	100	N/A	N/A	N	IDC	RD	0/17	residual cancer	P	90	2	4	FAC  x 6	H	1	1-26-06	MRM/ALND	1
GSM508052	breast cancer PERU45	GSM508052	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -9.34998957600692	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 10-12-05	age: 64	race: H	histology: IDC	prechemo t: 3	prechemo n: 0	bmn grade: 3	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 3-18-06	post chemo size cm: residual cancer	post chemo +ln/total: 0/15	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508052/suppl/GSM508052_FL416-PERU45.CEL.gz	22283	Reanalyzed by: GSE205568	64	Pass	10-12-05	3	0	-9.34998957600692	N	N/A	N/A	N/A	N	IDC	RD	0/15	residual cancer	N	N/A	0	3	FAC x 6  (Taxol post Sx)	H	1	3-18-06	MRM/ALND	1
GSM508053	breast cancer PERU61	GSM508053	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -30.9378941593022	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-13-06	age: 69	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: 3	er% positive: 80	er status: P	pr% positive: 80	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol x 12 post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 8-1-06	post chemo size cm: residual cancer	post chemo +ln/total: 0/21	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508053/suppl/GSM508053_FL426-PERU61.CEL.gz	22283	Reanalyzed by: GSE205568	69	Pass	1-13-06	3	0	-30.9378941593022	P	80	N/A	N/A	N	IDC	RD	0/21	residual cancer	P	80	1	4	FAC x 6  (Taxol x 12 post Sx)	H	1	8-1-06	MRM/ALND	1
GSM508054	breast cancer PERU53	GSM508054	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -7.01192426309535	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 12-19-05	age: 35	race: H	histology: IDC	prechemo t: 3	prechemo n: 1	bmn grade: 3	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol x 12 post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 6-23-06	post chemo size cm: residual cancer	post chemo +ln/total: 0/14	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508054/suppl/GSM508054_FL471-PERU53.CEL.gz	22283	Reanalyzed by: GSE205568	35	Pass	12-19-05	3	0	-7.01192426309535	N	N/A	N/A	N/A	N	IDC	RD	0/14	residual cancer	N	N/A	1	3	FAC x 6  (Taxol x 12 post Sx)	H	1	6-23-06	MRM/ALND	1
GSM508055	breast cancer PERU05	GSM508055	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -9.14388139873881	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-1-04	age: 38	race: H	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 2	er% positive: 90	er status: P	pr% positive: 70	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol x 12 post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 2-21-05	post chemo size cm: residual cancer	post chemo +ln/total: 0/24	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508055/suppl/GSM508055_29539_AB01723010_35704.CEL.gz	22283	Reanalyzed by: GSE205568	38	Pass	9-1-04	2	0	-9.14388139873881	P	90	N/A	N/A	N	IDC	RD	0/24	residual cancer	P	70	1	2	FAC x 6  (Taxol x 12 post Sx)	H	1	2-21-05	MRM/ALND	1
GSM508056	breast cancer PERU08	GSM508056	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -30.7905626686243	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-3-04	age: 40	race: H	histology: IDC	prechemo t: 3	prechemo n: 1	bmn grade: 3	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6   (Taxol x 10 post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 7-12-05	post chemo size cm: residual cancer	post chemo +ln/total: 0/29	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508056/suppl/GSM508056_FL1405_Peru8.CEL.gz	22283	Reanalyzed by: GSE205568	40	Pass	11-3-04	3	0	-30.7905626686243	N	N/A	N/A	N/A	N	IDC	RD	0/29	residual cancer	N	N/A	1	3	FAC x 6   (Taxol x 10 post Sx)	H	1	7-12-05	MRM/ALND	1
GSM508057	breast cancer PERU02	GSM508057	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 13.9087707250801	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 8-2-04	age: 71	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: 3	er% positive: 90	er status: P	pr% positive: 10	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6   (Taxol x 12 post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 3-15-05	post chemo size cm: residual cancer	post chemo +ln/total: 0/26	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508057/suppl/GSM508057_29539_AB01833512_35703.CEL.gz	22283	Reanalyzed by: GSE205568	71	Pass	8-2-04	3	1	13.9087707250801	P	90	N/A	N/A	N	IDC	RD	0/26	residual cancer	P	10	1	4	FAC x 6   (Taxol x 12 post Sx)	H	1	3-15-05	MRM/ALND	1
GSM508058	breast cancer PERU51	GSM508058	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 4.62049536285122	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 12-9-05	age: 74	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/ALND	surgery date: 6-24-06	post chemo size cm: residual cancer	post chemo +ln/total: 0/12		N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508058/suppl/GSM508058_FL419-PERU51.CEL.gz	22283	Reanalyzed by: GSE205568	74	Pass	12-9-05	N/A	1	4.62049536285122	N	NA	N/A	N/A	N	IDC	RD	0/12	residual cancer	N	N/A	1	4	FAC x 6	H	1	6-24-06	MRM/ALND	1
GSM508059	breast cancer PERU21	GSM508059	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -43.6777241344007	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 5-27-05	age: 36	race: H	histology: IDC	prechemo t: 3	prechemo n: 0	bmn grade: N/A	er% positive: 70	er status: P	pr% positive: 70	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC  x 6  (Taxol x 12 post Sx)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: MRM/LNB	surgery date: 11-8-05	post chemo size cm: N/A	post chemo +ln/total: 1/1	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508059/suppl/GSM508059_FL431-PERU21.CEL.gz	22283	Reanalyzed by: GSE205568	36	Pass	5-27-05	N/A	0	-43.6777241344007	P	70	N/A	N/A	N	IDC	RD	1/1	N/A	P	70	0	3	FAC  x 6  (Taxol x 12 post Sx)	H	1	11-8-05	MRM/LNB	1
GSM508060	breast cancer MEXICO18	GSM508060	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -15.5163897299117	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 8-26-05	age: 52	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: 2	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: N/A	surgery date: 4-28-06	post chemo size cm: N/A	post chemo +ln/total: 21/24	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508060/suppl/GSM508060_U133A_80-FL-230-FL394-GM18_09_29_06.CEL.gz	22283	Reanalyzed by: GSE205568	52	Pass	8-26-05	2	0	-15.5163897299117	N	0	N/A	0	N	IDC	RD	21/24	N/A	N	0	2	4	FEC x 6	H	1	4-28-06	N/A	1
GSM508061	breast cancer MEXICO15	GSM508061	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -28.1461009124559	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 8-31-05	age: 42	race: H	histology: IDC	prechemo t: 3	prechemo n: 0	bmn grade: N/A	er% positive: 0	er status: N	pr% positive: N/A	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: N/A	surgery date: 3-9-06	post chemo size cm: N/A	post chemo +ln/total: 2/20	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508061/suppl/GSM508061_FL411-GM15.CEL.gz	22283	Reanalyzed by: GSE205568	42	Pass	8-31-05	N/A	0	-28.1461009124559	N	0	N/A	0	N	IDC	RD	2/20	N/A	P	N/A	0	3	FEC x 6	H	1	3-9-06	N/A	1
GSM508062	breast cancer MEXICO10	GSM508062	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -19.703112785639	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 6-16-05	age: 45	race: H	histology: IDC	prechemo t: 4	prechemo n: 3	bmn grade: 2	er% positive: 0	er status: P	pr% positive: 0	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: N/A	surgery date: 1-5-06	post chemo size cm: N/A	post chemo +ln/total: 11/17	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508062/suppl/GSM508062_U133A_80-FL-229-FL393-GM10_09_29_06.CEL.gz	22283	Reanalyzed by: GSE205568	45	Pass	6-16-05	2	0	-19.703112785639	P	0	N/A	0	N	IDC	RD	11/17	N/A	P	0	3	4	FEC x 6	H	1	1-5-06	N/A	1
GSM508063	breast cancer MEXICO2	GSM508063	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -38.594639643321	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 8-10-04	age: 57	race: H	histology: IDC	prechemo t: 3	prechemo n: 1	bmn grade: N/A	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: N/A	surgery date: 1-13-05	post chemo size cm: N/A	post chemo +ln/total: 5/17	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508063/suppl/GSM508063_FL405-GM2.CEL.gz	22283	Reanalyzed by: GSE205568	57	Pass	8-10-04	N/A	0	-38.594639643321	N	0	N/A	0	N	IDC	RD	5/17	N/A	N	0	1	3	FEC x 6	H	1	1-13-05	N/A	1
GSM508064	breast cancer MEXICO12	GSM508064	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -9.22296661367363	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 6-13-05	age: 61	race: H	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: N/A	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: N/A	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: N/A	surgery date: 12-9-05	post chemo size cm: residual cancer	post chemo +ln/total: 0/13	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508064/suppl/GSM508064_FL410-GM12.CEL.gz	22283	Reanalyzed by: GSE205568	61	Pass	6-13-05	N/A	0	-9.22296661367363	N	0	N/A	3	P	IDC	RD	0/13	residual cancer	N	0	0	2	FEC x 6	H	1	12-9-05	N/A	1
GSM508065	breast cancer PERU75	GSM508065	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -24.9212890896342	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 5-15-06	age: 56	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: N/A	er% positive: 95	er status: P	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: ND	surgery date: ND	post chemo size cm: ND	post chemo +ln/total: ND	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508065/suppl/GSM508065_FL467-PERU75.CEL.gz	22283	Reanalyzed by: GSE205568	56	Pass	5-15-06	N/A	0	-24.9212890896342	P	95	N/A	N/A	N	IDC	RD	ND	ND	N	N/A	2	4	FAC x 6	H	1	ND	ND	1
GSM508066	breast cancer PERU22	GSM508066	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -20.8004056325426	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 6-13-05	age: 34	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: N/A	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 5(d/t P.D)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: ND	surgery date: ND	post chemo size cm: ND	post chemo +ln/total: ND	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508066/suppl/GSM508066_FL403-PERU22.CEL.gz	22283	Reanalyzed by: GSE205568	34	Pass	6-13-05	N/A	0	-20.8004056325426	N	N/A	N/A	N/A	N	IDC	RD	ND	ND	N	N/A	1	4	FAC x 5(d/t P.D)	H	1	ND	ND	1
GSM508067	breast cancer LBJ043	GSM508067	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -4.29208417748669	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-24-04	age: 49	race: B	histology: IDC/IBC	prechemo t: 4	prechemo n: 0	bmn grade: 3	er% positive: N/A	er status: P	pr% positive: N/A	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: 1.26	preoperative treatment: FAC x 4  (d/t P.D) Taxotere x 2 (d/t severe Dehydration) Xeloda x 2(d/t P.D) XRT+ Xeloda Taxol x 2	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: ND	surgery date: ND	post chemo size cm: ND	post chemo +ln/total: ND	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508067/suppl/GSM508067_FL433-LBJ43.CEL.gz	22283	Reanalyzed by: GSE205568	49	Pass	9-24-04	3	0	-4.29208417748669	P	N/A	1.26	0	N	IDC/IBC	RD	ND	ND	P	N/A	0	4	FAC x 4  (d/t P.D) Taxotere x 2 (d/t severe Dehydration) Xeloda x 2(d/t P.D) XRT+ Xeloda Taxol x 2	B	1	ND	ND	1
GSM508068	breast cancer PERU43	GSM508068	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 11.6167139989884	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 10-3-05	age: 68	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: N/A	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 3 (D/T PD) Taxol x 4	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: ND	surgery date: ND	post chemo size cm: ND	post chemo +ln/total: ND	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508068/suppl/GSM508068_FL464-PERU43.CEL.gz	22283	Reanalyzed by: GSE205568	68	Pass	10-3-05	N/A	1	11.6167139989884	N	N/A	N/A	N/A	N	IDC	RD	ND	ND	N	N/A	2	4	FAC x 3 (D/T PD) Taxol x 4	H	1	ND	ND	1
GSM508069	breast cancer PERU49	GSM508069	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 20.2583395574184	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 11-9-05	age: 36	race: H	histology: IDC	prechemo t: 3	prechemo n: 2	bmn grade: N/A	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 4 (D/T P.D.)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: ND	surgery date: ND	post chemo size cm: ND	post chemo +ln/total: ND	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508069/suppl/GSM508069_FL417-PERU49.CEL.gz	22283	Reanalyzed by: GSE205568	36	Pass	11-9-05	N/A	1	20.2583395574184	N	N/A	N/A	N/A	N	IDC	RD	ND	ND	N	N/A	2	3	FAC x 4 (D/T P.D.)	H	1	ND	ND	1
GSM508070	breast cancer PERU15-17	GSM508070	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 15.4037464356843	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 1-31-05	age: 49	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: N/A	er% positive: 30	er status: P	pr% positive: N/A	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: N/A	preoperative treatment: FAC  x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: ND for liver mets	surgery date: ND	post chemo size cm: ND	post chemo +ln/total: ND	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508070/suppl/GSM508070_29539_AB01833782_35651.CEL.gz	22283	Reanalyzed by: GSE205568	49	Pass	1-31-05	N/A	1	15.4037464356843	P	30	N/A	3	P	IDC	RD	ND	ND	N	N/A	2	4	FAC  x 6	H	1	ND	ND for liver mets	1
GSM508071	breast cancer SPAIN34	GSM508071	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 15.3894458560862	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 10-1-06	age: 59	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 1	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: FEC x(6)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Quadrantectomy	surgery date: 2-6-06	post chemo size cm: 0	post chemo +ln/total: 0/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508071/suppl/GSM508071_FL740-Spain34.CEL.gz	22283	Reanalyzed by: GSE205568	59	Pass	10-1-06	3	1	15.3894458560862	N	0	ND	0	N	Infiltrating Ductal Carcinoma	pCR	0/18	0	N	0	1	2	FEC x(6)	W	1	2-6-06	Quadrantectomy	1
GSM508072	breast cancer SPAIN5	GSM508072	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 19.3473791183205	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 7-29-05	age: 49	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: ND	preoperative treatment: FEC x( 6)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Quadrantectomy	surgery date: 1-19-06	post chemo size cm: 1.5	post chemo +ln/total: 1/14	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508072/suppl/GSM508072_FL1303_GM5.CEL.gz	22283	Reanalyzed by: GSE205568	49	Pass	7-29-05	3	1	19.3473791183205	N	0	ND	3	P	Infiltrating Ductal Carcinoma	RD	1/14	1.5	N	0	0	2	FEC x( 6)	W	1	1-19-06	Quadrantectomy	1
GSM508073	breast cancer SPAIN9	GSM508073	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -14.7022012817779	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-19-05	age: 60	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 100	er status: P	pr% positive: 60	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: FEC x(6 )	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Quadrantectomy	surgery date: 2-13-06	post chemo size cm: 1.7	post chemo +ln/total: 0/13	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508073/suppl/GSM508073_FL991-Spain9-core.CEL.gz	22283	Reanalyzed by: GSE205568	60	Pass	9-19-05	3	0	-14.7022012817779	P	100	ND	0	N	Infiltrating Ductal Carcinoma	RD	0/13	1.7	P	60	0	2	FEC x(6 )	W	1	2-13-06	Quadrantectomy	1
GSM508074	breast cancer SPAIN1	GSM508074	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -20.1330155802079	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 7-29-05	age: 56	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 3	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: FEC x(6 )	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Quadrantectomy	surgery date: 12-20-05	post chemo size cm: 1.8	post chemo +ln/total: 0/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508074/suppl/GSM508074_FL1302_GM1.CEL.gz	22283	Reanalyzed by: GSE205568	56	Pass	7-29-05	3	0	-20.1330155802079	N	0	ND	0	N	Infiltrating Ductal Carcinoma	RD	0/18	1.8	N	0	0	3	FEC x(6 )	W	1	12-20-05	Quadrantectomy	1
GSM508075	breast cancer SPAIN59	GSM508075	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -1.10475521724766	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-4-06	age: 44	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 1	bmn grade: 2	er% positive: 70	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: ND	preoperative treatment: FEC x( 6)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Quadrantectomy	surgery date: 8-30-06	post chemo size cm: 2	post chemo +ln/total: 1/14	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508075/suppl/GSM508075_FL744-spain59.CEL.gz	22283	Reanalyzed by: GSE205568	44	Pass	11-4-06	2	0	-1.10475521724766	P	70	ND	1	N	Infiltrating Ductal Carcinoma	RD	1/14	2	P	90	1	2	FEC x( 6)	W	1	8-30-06	Quadrantectomy	1
GSM508076	breast cancer SPAIN38	GSM508076	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -13.4195400379376	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-30-06	age: 47	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 85	er status: P	pr% positive: 95	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: ND	preoperative treatment: FEC x(6 )	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Quadrantectomy	surgery date: 6-30-06	post chemo size cm: 2	post chemo +ln/total: 0/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508076/suppl/GSM508076_FL719-Spain38.CEL.gz	22283	Reanalyzed by: GSE205568	47	Pass	1-30-06	2	0	-13.4195400379376	P	85	ND	1	N	Infiltrating Ductal Carcinoma	RD	0/18	2	P	95	0	2	FEC x(6 )	W	1	6-30-06	Quadrantectomy	1
GSM508077	breast cancer SPAIN39	GSM508077	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -34.5607689088465	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-1-06	age: 45	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: N/A	bmn grade: 2	er% positive: 25-50	er status: P	pr% positive: 25-50	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: FEC x( 6)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Quadrantectomy	surgery date: 7-26-06	post chemo size cm: 2.5	post chemo +ln/total: 1/7	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508077/suppl/GSM508077_FL1304_GM39.CEL.gz	22283	Reanalyzed by: GSE205568	45	Pass	11-1-06	2	0	-34.5607689088465	P	25-50	ND	0	N	Infiltrating Ductal Carcinoma	RD	1/7	2.5	P	25-50	N/A	2	FEC x( 6)	W	1	7-26-06	Quadrantectomy	1
GSM508078	breast cancer SPAIN40	GSM508078	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -18.8399004610437	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 7-2-06	age: 59	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 80	er status: P	pr% positive: 2	pr status: P	her 2 status: P	her 2 ihc: 3	her 2 fish: 8	preoperative treatment: FEC x(6 )	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: Quadrantectomy	surgery date: 7-25-06	post chemo size cm: 3.2	post chemo +ln/total: 0/19	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508078/suppl/GSM508078_FL720-SPAIN40.CEL.gz	22283	Reanalyzed by: GSE205568	59	Pass	7-2-06	3	0	-18.8399004610437	P	80	8	3	P	Infiltrating Ductal Carcinoma	RD	0/19	3.2	P	2	0	2	FEC x(6 )	W	1	7-25-06	Quadrantectomy	1
GSM508079	breast cancer 444	GSM508079	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 2.75060223831679	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 8-5-04	age: 53	race: W	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 3	er% positive: 90	er status: P	pr% positive: 5	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: 0.83	preoperative treatment: FAC x 6 (neo-adj)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: SM/ALND	surgery date: 1-5-05	post chemo size cm: 0	post chemo +ln/total: 2/23	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508079/suppl/GSM508079_U133A_FL56_444_07_20_05.CEL.gz	22283	Reanalyzed by: GSE205568	53	Pass	8-5-04	3	1	2.75060223831679	P	90	0.83	N/A	N	IDC	RD	2/23	0	N	5	1	2	FAC x 6 (neo-adj)	W	1	1-5-05	SM/ALND	1
GSM508080	breast cancer 633	GSM508080	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 24.140687000041	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 7-6-05	age: 46	race: B	histology: IDC	prechemo t: 2	prechemo n: 2	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: 0.77	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: SM/ALND	surgery date: 2-15-06	post chemo size cm: 0.8	post chemo +ln/total: 0/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508080/suppl/GSM508080_FL400-633.CEL.gz	22283	Reanalyzed by: GSE205568	46	Pass	7-6-05	3	1	24.140687000041	N	0	0.77	N/A	N	IDC	RD	0/18	0.8	N	0	2	2	FAC x 6	B	1	2-15-06	SM/ALND	1
GSM508081	breast cancer 349	GSM508081	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -32.2539718549324	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-15-04	age: 40	race: W	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 100	er status: P	pr% positive: 50	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FAC x 6 (neo-adj); Taxol x 12 (adj); Tamoxifen	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: SM/ALND	surgery date: 6-25-04	post chemo size cm: 1.1	post chemo +ln/total: 1/5	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508081/suppl/GSM508081_U133A_FL57-349_07_27_05.CEL.gz	22283	Reanalyzed by: GSE205568	40	Pass	1-15-04	2	0	-32.2539718549324	P	100	N/A	0	N	IDC	RD	1/5	1.1	P	50	0	2	FAC x 6 (neo-adj); Taxol x 12 (adj); Tamoxifen	W	1	6-25-04	SM/ALND	1
GSM508082	breast cancer 632	GSM508082	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -37.5558829077781	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 8-15-05	age: 48	race: H	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 2	er% positive: 90	er status: P	pr% positive: 75	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: 1.41	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: SM/ALND	surgery date: 2-20-06	post chemo size cm: 2.1	post chemo +ln/total: 4/10	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508082/suppl/GSM508082_U133A_80-FL-218-FL382-632_09_08_06.CEL.gz	22283	Reanalyzed by: GSE205568	48	Pass	8-15-05	2	0	-37.5558829077781	P	90	1.41	1	N	IDC	RD	4/10	2.1	P	75	1	2	FAC x 6	H	1	2-20-06	SM/ALND	1
GSM508083	breast cancer 629	GSM508083	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -31.0575013214839	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 8-10-05	age: 61	race: W	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 1	er% positive: 25	er status: P	pr% positive: 10	pr status: P	her 2 status: N	her 2 ihc: 2	her 2 fish: 0.97	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: SM/ALND	surgery date: 2-1-06	post chemo size cm: 2.3	post chemo +ln/total: 0/7	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508083/suppl/GSM508083_U133A_80-FL-216-FL380-629_09_08_06.CEL.gz	22283	Reanalyzed by: GSE205568	61	Pass	8-10-05	1	0	-31.0575013214839	P	25	0.97	2	N	IDC	RD	0/7	2.3	P	10	0	2	FAC x 6	W	1	2-1-06	SM/ALND	1
GSM508084	breast cancer 604	GSM508084	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -19.6836051837035	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 6-29-05	age: 62	race: H	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 100	er status: P	pr% positive: 100	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: 0.93	preoperative treatment: FAC x 5	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: SM/ALND	surgery date: 1-11-06	post chemo size cm: 2.5	post chemo +ln/total: 2/7	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508084/suppl/GSM508084_U133A_80-FL-215-FL379-604_09_08_06.CEL.gz	22283	Reanalyzed by: GSE205568	62	Pass	6-29-05	2	0	-19.6836051837035	P	100	0.93	N/A	N	IDC	RD	2/7	2.5	P	100	0	2	FAC x 5	H	1	1-11-06	SM/ALND	1
GSM508085	breast cancer 570	GSM508085	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 18.8046146310462	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 4-7-05	age: 46	race: B	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 1	her 2 fish: 0.87	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: SM/ALND	surgery date: 9-30-05	post chemo size cm: 3	post chemo +ln/total: 17/22	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508085/suppl/GSM508085_U133A_80-FL-205-FL369-570_08_25_06.CEL.gz	22283	Reanalyzed by: GSE205568	46	Pass	4-7-05	3	1	18.8046146310462	N	0	0.87	1	N	IDC	RD	17/22	3	N	0	2	4	FEC x 6	B	1	9-30-05	SM/ALND	1
GSM508086	breast cancer PERU77	GSM508086	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 2.24507573891606	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 6-9-06	age: 47	race: H	histology: IDC	prechemo t: 3	prechemo n: 1	bmn grade: 2	er% positive: 95	er status: N	pr% positive: 95	pr status: N	her 2 status: P	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: FAC x 6  (Taxol x 6 post Sx - still under adj chemo)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: SM/ALND	surgery date: 12-9-06	post chemo size cm: N/A	post chemo +ln/total: 3/11	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508086/suppl/GSM508086_FL841-Peru77.CEL.gz	22283	Reanalyzed by: GSE205568	47	Pass	6-9-06	2	1	2.24507573891606	N	95	N/A	N/A	P	IDC	RD	3/11	N/A	N	95	1	3	FAC x 6  (Taxol x 6 post Sx - still under adj chemo)	H	1	12-9-06	SM/ALND	1
GSM508087	breast cancer 622	GSM508087	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: -10.9354134274581	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 8-16-05	age: 59	race: W	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FAC x 4 (stopped after 4 of 6 planned cycles d/t nausea fatigue fever)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: SM/LNB	surgery date: 12-28-05	post chemo size cm: 0	post chemo +ln/total: 0/4	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508087/suppl/GSM508087_FL1307_622.CEL.gz	22283	Reanalyzed by: GSE205568	59	Pass	8-16-05	3	0	-10.9354134274581	N	0	N/A	0	N	IDC	pCR	0/4	0	N	0	0	2	FAC x 4 (stopped after 4 of 6 planned cycles d/t nausea fatigue fever)	W	1	12-28-05	SM/LNB	1
GSM508088	breast cancer 702	GSM508088	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -41.4907342833903	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 2-9-06	age: 49	race: W	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 70	er status: P	pr% positive: 95	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FEC x 5	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: SM/LNB	surgery date: 6-30-06	post chemo size cm: 1	post chemo +ln/total: 0/3	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508088/suppl/GSM508088_FL386-702-2.CEL.gz	22283	Reanalyzed by: GSE205568	49	Pass	2-9-06	2	0	-41.4907342833903	P	70	N/A	0	N	IDC	RD	0/3	1	P	95	0	2	FEC x 5	W	1	6-30-06	SM/LNB	1
GSM508089	breast cancer 694	GSM508089	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 18.4850098117404	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 2-1-06	age: 38	race: W	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: SM/LNB	surgery date: 7-27-06	post chemo size cm: 1.3	post chemo +ln/total: 2/28	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508089/suppl/GSM508089_FL385-694-2.CEL.gz	22283	Reanalyzed by: GSE205568	38	Pass	2-1-06	3	1	18.4850098117404	N	0	N/A	0	N	IDC	RD	2/28	1.3	N	0	1	2	FAC x 6	W	1	7-27-06	SM/LNB	1
GSM508090	breast cancer 414	GSM508090	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 0.932344753313373	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 5-24-04	age: 66	race: W	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 3	er status: N	pr% positive: 3	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: SM/LNB	surgery date: 11-22-04	post chemo size cm: 2	post chemo +ln/total: 0/3	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508090/suppl/GSM508090_U133A_FL55_414_07_20_05.CEL.gz	22283	Reanalyzed by: GSE205568	66	Pass	5-24-04	3	1	0.932344753313373	N	3	N/A	0	N	IDC	RD	0/3	2	N	3	0	2	FAC x 6	W	1	11-22-04	SM/LNB	1
GSM508091	breast cancer 521	GSM508091	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 11.0642011030777	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 12-23-04	age: 31	race: H	histology: IDC	prechemo t: 3	prechemo n: 1	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 2	her 2 fish: 1.04	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: SM/LNB	surgery date: 6-22-05	post chemo size cm: 3	post chemo +ln/total: 0/10	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508091/suppl/GSM508091_U133A_FL99_521_10_05_05.CEL.gz	22283	Reanalyzed by: GSE205568	31	Pass	12-23-04	3	1	11.0642011030777	N	0	1.04	2	N	IDC	RD	0/10	3	N	0	1	3	FAC x 6	H	1	6-22-05	SM/LNB	1
GSM508092	breast cancer 461	GSM508092	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -17.7220121977589	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 7-8-04	age: 44	race: H	histology: IDC	prechemo t: 0	prechemo n: 2	bmn grade: 3	er% positive: 90	er status: P	pr% positive: 10	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: TM/ALND	surgery date: 4-5-05	post chemo size cm: 0.5	post chemo +ln/total: 2/24	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508092/suppl/GSM508092_U133A_FL67-461_08_04_05.CEL.gz	22283	Reanalyzed by: GSE205568	44	Pass	7-8-04	3	0	-17.7220121977589	P	90	N/A	0	N	IDC	RD	2/24	0.5	P	10	2	0	FEC x 6	H	1	4-5-05	TM/ALND	1
GSM508093	breast cancer 369	GSM508093	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 8.33017049333648	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 3-2-04	age: 52	race: W	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.29	preoperative treatment: FEC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: TM/ALND	surgery date: 8-3-04	post chemo size cm: 0.5	post chemo +ln/total: 0/29	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508093/suppl/GSM508093_U133A_FL62-369_07_28_05.CEL.gz	22283	Reanalyzed by: GSE205568	52	Pass	3-2-04	2	1	8.33017049333648	N	0	1.29	N/A	N	IDC	RD	0/29	0.5	N	0	0	2	FEC x 6	W	1	8-3-04	TM/ALND	1
GSM508094	breast cancer 536	GSM508094	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -30.8551074574534	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-12-05	age: 43	race: W	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 2	er% positive: 20	er status: P	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 1	her 2 fish: 1.17	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: TM/ALND	surgery date: 7-13-05	post chemo size cm: 1.2	post chemo +ln/total: 1/15	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508094/suppl/GSM508094_U133A_FL100_536_10_05_05.CEL.gz	22283	Reanalyzed by: GSE205568	43	Pass	1-12-05	2	0	-30.8551074574534	P	20	1.17	1	N	IDC	RD	1/15	1.2	N	0	1	2	FAC x 6	W	1	7-13-05	TM/ALND	1
GSM508095	breast cancer 680	GSM508095	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -23.4442540133405	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-12-06	age: 34	race: H	histology: IDC	prechemo t: 2	prechemo n: 2	bmn grade: 2	er% positive: 90	er status: P	pr% positive: 30	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: 1.74	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: TM/ALND	surgery date: 6-9-06	post chemo size cm: 2.2	post chemo +ln/total: 1/14	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508095/suppl/GSM508095_FL384-680-2.CEL.gz	22283	Reanalyzed by: GSE205568	34	Pass	1-12-06	2	0	-23.4442540133405	P	90	1.74	1	N	IDC	RD	1/14	2.2	P	30	2	2	FAC x 6	H	1	6-9-06	TM/ALND	1
GSM508096	breast cancer 705	GSM508096	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 1.57921274334331	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 2-27-06	age: 48	race: W	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 2	er% positive: 5	er status: N	pr% positive: 2	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: TM/LNB	surgery date: 7-31-06	post chemo size cm: 1.4	post chemo +ln/total: 0/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508096/suppl/GSM508096_FL453-705.CEL.gz	22283	Reanalyzed by: GSE205568	48	Pass	2-27-06	2	1	1.57921274334331	N	5	N/A	0	N	IDC	RD	0/18	1.4	N	2	1	2	FAC x 6	W	1	7-31-06	TM/LNB	1
GSM508097	breast cancer 703	GSM508097	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -27.3135691560819	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-13-06	age: 57	race: B	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 2	her 2 fish: 1.17	preoperative treatment: FAC x 6	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: TM/LNB	surgery date: 7-28-06	post chemo size cm: 2.2	post chemo +ln/total: 0/1	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508097/suppl/GSM508097_FL1290_703.CEL.gz	22283	Reanalyzed by: GSE205568	57	Pass	1-13-06	2	0	-27.3135691560819	N	0	1.17	2	N	IDC	RD	0/1	2.2	N	0	0	2	FAC x 6	B	1	7-28-06	TM/LNB	1
GSM508098	breast cancer 755	GSM508098	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -33.6557905916252	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 8-1-06	age: 73	race: W	histology: IDC	prechemo t: 4	prechemo n: 0	bmn grade: 2	er% positive: 90	er status: P	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 2	her 2 fish: 1.02	preoperative treatment: FEC x  4 (original planned was 6 cycles disc. due to anorexia)	treatment received (1=fac, 2=t/fac): 1	randomized (1=fac, 2=t/fac): 1	surgery type: TM/LNB	surgery date: 12-1-06	post chemo size cm: 3	post chemo +ln/total: 1/2	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508098/suppl/GSM508098_FL798-755.CEL.gz	22283	Reanalyzed by: GSE205568	73	Pass	8-1-06	2	0	-33.6557905916252	P	90	1.02	2	N	IDC	RD	1/2	3	N	0	0	4	FEC x  4 (original planned was 6 cycles disc. due to anorexia)	W	1	12-1-06	TM/LNB	1
GSM508099	breast cancer SPAIN47	GSM508099	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 5.22922407599253	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 2-23-06	age: 49	race: W	histology: Only Infiltrating	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Lumpectomy	surgery date: 12-9-06	post chemo size cm: 0	post chemo +ln/total: 0/2	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508099/suppl/GSM508099_FL722-sapin47.CEL.gz	22283	Reanalyzed by: GSE205568	49	Pass	2-23-06	3	1	5.22922407599253	N	0	ND	3	P	Only Infiltrating	pCR	0/2	0	N	0	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	12-9-06	Lumpectomy	2
GSM508100	breast cancer SPAIN7	GSM508100	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -16.1217546338085	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 7-9-05	age: 37	race: H	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 40	er status: P	pr% positive: 80	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Lumpectomy	surgery date: 4-4-06	post chemo size cm: 1	post chemo +ln/total: 0	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508100/suppl/GSM508100_FL718-Spain7.CEL.gz	22283	Reanalyzed by: GSE205568	37	Pass	7-9-05	2	0	-16.1217546338085	P	40	ND	0	N	Infiltrating Ductal Carcinoma	RD	0	1	P	80	0	2	Paclitaxel x(12 )  + FEC x(4 )	H	2	4-4-06	Lumpectomy	2
GSM508101	breast cancer SPAIN25	GSM508101	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -3.01171221074583	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-25-05	age: 66	race: W	histology: Mixed; Ductal and Lobular	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 90	er status: P	pr% positive: 70	pr status: P	her 2 status: P	her 2 ihc: 2	her 2 fish: 2.4	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Lumpectomy	surgery date: 5-6-06	post chemo size cm: 1	post chemo +ln/total: 0/23	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508101/suppl/GSM508101_FL738-Spain25.CEL.gz	22283	Reanalyzed by: GSE205568	66	Pass	11-25-05	2	0	-3.01171221074583	P	90	2.4	2	P	Mixed; Ductal and Lobular	RD	0/23	1	P	70	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	5-6-06	Lumpectomy	2
GSM508102	breast cancer SPAIN18	GSM508102	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 2.65200930188075	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 4-11-05	age: 47	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 1	bmn grade: 2	er% positive: 75	er status: P	pr% positive: 25	pr status: P	her 2 status: P	her 2 ihc: 3	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Lumpectomy	surgery date: 5-15-06	post chemo size cm: 1.9	post chemo +ln/total: 1/13	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508102/suppl/GSM508102_FL848-Spain18.CEL.gz	22283	Reanalyzed by: GSE205568	47	Pass	4-11-05	2	1	2.65200930188075	P	75	ND	3	P	Infiltrating Ductal Carcinoma	RD	1/13	1.9	P	25	1	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	5-15-06	Lumpectomy	2
GSM508103	breast cancer SPAIN57	GSM508103	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -40.1872561112541	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-4-06	age: 46	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 0	bmn grade: 1	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Lumpectomy	surgery date: 10-17-06	post chemo size cm: 2.3	post chemo +ln/total: 2/23	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508103/suppl/GSM508103_FL742-Spain57.CEL.gz	22283	Reanalyzed by: GSE205568	46	Pass	11-4-06	1	0	-40.1872561112541	N	0	ND	0	N	Infiltrating Ductal Carcinoma	RD	2/23	2.3	N	0	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	10-17-06	Lumpectomy	2
GSM508104	breast cancer SPAIN48	GSM508104	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: -21.2006007588261	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 8-3-06	age: 46	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 2	her 2 fish: 1.5	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Mastectomy	surgery date: 4-9-06	post chemo size cm: 0	post chemo +ln/total: 0/20	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508104/suppl/GSM508104_FL723-spain48.CEL.gz	22283	Reanalyzed by: GSE205568	46	Pass	8-3-06	3	0	-21.2006007588261	N	0	1.5	2	N	Infiltrating Ductal Carcinoma	pCR	0/20	0	N	0	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	4-9-06	Mastectomy	2
GSM508105	breast cancer SPAIN45	GSM508105	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 10.1704326290164	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 2-27-06	age: 56	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 4	prechemo n: 1	bmn grade: N/A	er% positive: 70	er status: P	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x(3 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Mastectomy	surgery date: 8-28-06	post chemo size cm: 0	post chemo +ln/total: 0/14	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508105/suppl/GSM508105_FL721-spain45.CEL.gz	22283	Reanalyzed by: GSE205568	56	Pass	2-27-06	N/A	1	10.1704326290164	P	70	ND	0	N	Infiltrating Ductal Carcinoma	pCR	0/14	0	N	0	1	4	Paclitaxel x(12 )  + FEC x(3 )	W	2	8-28-06	Mastectomy	2
GSM508106	breast cancer SPAIN53	GSM508106	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -5.97478888166916	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 10-3-06	age: 71	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 1	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 2	her 2 fish: 0	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Mastectomy	surgery date: 4-9-06	post chemo size cm: 0.26	post chemo +ln/total: 3/25	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508106/suppl/GSM508106_FL724-spain53.CEL.gz	22283	Reanalyzed by: GSE205568	71	Pass	10-3-06	3	0	-5.97478888166916	N	0	0	2	N	Infiltrating Ductal Carcinoma	RD	3/25	0.26	N	0	1	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	4-9-06	Mastectomy	2
GSM508107	breast cancer SPAIN27	GSM508107	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -38.0348753415328	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-14-05	age: 61	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 100	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: 2	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x( 4)	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Mastectomy	surgery date: 4-7-06	post chemo size cm: 1	post chemo +ln/total: 0/17	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508107/suppl/GSM508107_FL849-Spain27.CEL.gz	22283	Reanalyzed by: GSE205568	61	Pass	11-14-05	2	0	-38.0348753415328	P	100	ND	2	N	Infiltrating Ductal Carcinoma	RD	0/17	1	P	90	0	2	Paclitaxel x(12 )  + FEC x( 4)	W	2	4-7-06	Mastectomy	2
GSM508108	breast cancer SPAIN14	GSM508108	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -33.0449118171455	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 10-14-05	age: 66	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 1	prechemo n: 1	bmn grade: 1	er% positive: 70	er status: P	pr% positive: 30	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: Paclitaxel x(12)  + FEC x(3 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Mastectomy	surgery date: 4-20-06	post chemo size cm: 1	post chemo +ln/total: 2/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508108/suppl/GSM508108_FL404-Spain14-2.CEL.gz	22283	Reanalyzed by: GSE205568	66	Pass	10-14-05	1	0	-33.0449118171455	P	70	ND	0	N	Infiltrating Ductal Carcinoma	RD	2/18	1	P	30	1	1	Paclitaxel x(12)  + FEC x(3 )	W	2	4-20-06	Mastectomy	2
GSM508109	breast cancer SPAIN60	GSM508109	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -10.1894984041191	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-4-06	age: 45	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 0	bmn grade: 1	er% positive: 15	er status: P	pr% positive: 100	pr status: P	her 2 status: P	her 2 ihc: 3	her 2 fish: 1	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Mastectomy	surgery date: 10-16-06	post chemo size cm: 1	post chemo +ln/total: 0/20	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508109/suppl/GSM508109_FL726-spain60.CEL.gz	22283	Reanalyzed by: GSE205568	45	Pass	11-4-06	1	0	-10.1894984041191	P	15	1	3	P	Infiltrating Ductal Carcinoma	RD	0/20	1	P	100	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	10-16-06	Mastectomy	2
GSM508110	breast cancer SPAIN13	GSM508110	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -10.0085848108429	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-23-05	age: 42	race: W	histology: Inflitrating Lobular Carcinoma	prechemo t: 3	prechemo n: 0	bmn grade: 1	er% positive: 90	er status: P	pr% positive: 70	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: 1	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Mastectomy	surgery date: 3-21-06	post chemo size cm: 1.5	post chemo +ln/total: 2/16	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508110/suppl/GSM508110_FL847-Spain13.CEL.gz	22283	Reanalyzed by: GSE205568	42	Pass	9-23-05	1	0	-10.0085848108429	P	90	1	1	N	Inflitrating Lobular Carcinoma	RD	2/16	1.5	P	70	0	3	Paclitaxel x(12 )  + FEC x(4 )	W	2	3-21-06	Mastectomy	2
GSM508111	breast cancer SPAIN4	GSM508111	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 16.8288492103784	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 5-8-05	age: 68	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 3	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 2	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x( 4)	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Mastectomy	surgery date: 9-12-05	post chemo size cm: 2.9	post chemo +ln/total: 0/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508111/suppl/GSM508111_FL844-Spain4.CEL.gz	22283	Reanalyzed by: GSE205568	68	Pass	5-8-05	3	1	16.8288492103784	N	0	ND	2	N	Infiltrating Ductal Carcinoma	RD	0/18	2.9	N	0	0	3	Paclitaxel x(12 )  + FEC x( 4)	W	2	9-12-05	Mastectomy	2
GSM508112	breast cancer SPAIN46	GSM508112	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 1.14419624144466	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 1-3-06	age: 45	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 3	prechemo n: 1	bmn grade: 3	er% positive: 68	er status: P	pr% positive: 50	pr status: P	her 2 status: P	her 2 ihc: 3	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Mastectomy	surgery date: 8-30-06	post chemo size cm: 7.2	post chemo +ln/total: 8/14	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508112/suppl/GSM508112_FL853-Spain46.CEL.gz	22283	Reanalyzed by: GSE205568	45	Pass	1-3-06	3	1	1.14419624144466	P	68	ND	3	P	Infiltrating Ductal Carcinoma	RD	8/14	7.2	P	50	1	3	Paclitaxel x(12 )  + FEC x(4 )	W	2	8-30-06	Mastectomy	2
GSM508113	breast cancer SPAIN16	GSM508113	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 37.0947392057806	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 10-17-05	age: 31	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 4	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x( 0)	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Mastectomy	surgery date: 1-31-06	post chemo size cm: 12	post chemo +ln/total: 2/15	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508113/suppl/GSM508113_FL1667_Spain16.CEL.gz	22283	Reanalyzed by: GSE205568	31	Pass	10-17-05	3	1	37.0947392057806	N	0	ND	0	N	Infiltrating Ductal Carcinoma	RD	2/15	12	N	0	0	4	Paclitaxel x(12 )  + FEC x( 0)	W	2	1-31-06	Mastectomy	2
GSM508114	breast cancer 443	GSM508114	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: -21.5871601866784	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 7-20-04	age: 46	race: W	histology: IDC	prechemo t: 3	prechemo n: 2	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: 6	preoperative treatment: Taxol x 12 FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 2-18-05	post chemo size cm: 0	post chemo +ln/total: 0/10	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508114/suppl/GSM508114_U133A_80-FL-095_FL271-443_05_11_06.CEL.gz	22283	Reanalyzed by: GSE205568	46	Pass	7-20-04	3	0	-21.5871601866784	N	0	6	3	P	IDC	pCR	0/10	0	N	0	2	3	Taxol x 12 FEC x 4	W	2	2-18-05	MRM	2
GSM508115	breast cancer 331	GSM508115	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 10.8096866577325	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 12-12-03	age: 71	race: H	histology: IDC	prechemo t: 1	prechemo n: 1	bmn grade: 2	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: 9.26	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 7-8-04	post chemo size cm: 0	post chemo +ln/total: 0/17	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508115/suppl/GSM508115_28998_AB02090710_34885.CEL.gz	22283	Reanalyzed by: GSE205568	71	Pass	12-12-03	2	1	10.8096866577325	N	0	9.26	3	P	IDC	pCR	0/17	0	N	0	1	1	Taxol x 12 FAC x 4	H	2	7-8-04	MRM	2
GSM508116	breast cancer 485	GSM508116	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 54.7260883097388	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 10-4-04	age: 50	race: W	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: 3	er% positive: 1	er status: N	pr% positive: 1	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.04	preoperative treatment: Taxol x 11( Pt missed the first D/T shingles),  FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 5-6-05	post chemo size cm: 0	post chemo +ln/total: 0/20	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508116/suppl/GSM508116_29539_AB01833699_35605.CEL.gz	22283	Reanalyzed by: GSE205568	50	Pass	10-4-04	3	1	54.7260883097388	N	1	1.04	N/A	N	IDC	pCR	0/20	0	N	1	2	4	Taxol x 11( Pt missed the first D/T shingles),  FAC x 4	W	2	5-6-05	MRM	2
GSM508117	breast cancer 565	GSM508117	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -38.7577192825102	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 4-15-05	age: 57	race: W	histology: IDC	prechemo t: 1	prechemo n: 2	bmn grade: 3	er% positive: 100	er status: P	pr% positive: 100	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: 1.02	preoperative treatment: Taxol x 12 FAC x 6	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 12-14-05	post chemo size cm: 0	post chemo +ln/total: 2/30	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508117/suppl/GSM508117_U133A_80_FL_083_FL259-565_04_20_06.CEL.gz	22283	Reanalyzed by: GSE205568	57	Pass	4-15-05	3	0	-38.7577192825102	P	100	1.02	1	N	IDC	RD	2/30	0	P	100	2	1	Taxol x 12 FAC x 6	W	2	12-14-05	MRM	2
GSM508118	breast cancer 332	GSM508118	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 11.1979858602172	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 12-19-03	age: 42	race: W	histology: IDC	prechemo t: 3	prechemo n: 1	bmn grade: 3	er% positive: 50	er status: P	pr% positive: 10	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.09	preoperative treatment: Taxol x 6 (d/t P.D)   FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 5-26-04	post chemo size cm: 0.2	post chemo +ln/total: 0/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508118/suppl/GSM508118_U133A_80_FL_079_FL255-332_04_18_06.CEL.gz	22283	Reanalyzed by: GSE205568	42	Pass	12-19-03	3	1	11.1979858602172	P	50	1.09	N/A	N	IDC	RD	0/18	0.2	P	10	1	3	Taxol x 6 (d/t P.D)   FAC x 4	W	2	5-26-04	MRM	2
GSM508119	breast cancer 423	GSM508119	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 17.5399383273962	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 5-4-04	age: 68	race: B	histology: IDC	prechemo t: 0	prechemo n: 3	bmn grade: 2	er% positive: 10	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol x 12 FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 1-5-05	post chemo size cm: 0.7	post chemo +ln/total: 5/9	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508119/suppl/GSM508119_U133A_80_FL_082_FL258-423_04_18_06.CEL.gz	22283	Reanalyzed by: GSE205568	68	Pass	5-4-04	2	1	17.5399383273962	P	10	N/A	0	N	IDC	RD	5/9	0.7	P	90	3	0	Taxol x 12 FEC x 4	B	2	1-5-05	MRM	2
GSM508120	breast cancer PERU07	GSM508120	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -19.3136402280634	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 10-15-04	age: 71	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: 3	er% positive: 30	er status: P	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: 1	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 5-12-05	post chemo size cm: 1	post chemo +ln/total: 2/10	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508120/suppl/GSM508120_29539_AB01833754_35654.CEL.gz	22283	Reanalyzed by: GSE205568	71	Pass	10-15-04	3	0	-19.3136402280634	P	30	N/A	1	N	IDC	RD	2/10	1	N	N/A	1	4	Taxol x 12 FAC x 4	H	2	5-12-05	MRM	2
GSM508121	breast cancer PERU09	GSM508121	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -6.5808150731209	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-29-04	age: 47	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: 2	er% positive: 50	er status: P	pr% positive: 80	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 7-5-05	post chemo size cm: 1	post chemo +ln/total: 3/21	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508121/suppl/GSM508121_29539_AB01833820_35655.CEL.gz	22283	Reanalyzed by: GSE205568	47	Pass	11-29-04	2	0	-6.5808150731209	P	50	N/A	N/A	N	IDC	RD	3/21	1	P	80	1	4	Taxol x 12 FAC x 4	H	2	7-5-05	MRM	2
GSM508122	breast cancer PERU01	GSM508122	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -20.9477887370504	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 7-21-04	age: 73	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: 2	er% positive: 100	er status: P	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 2-21-05	post chemo size cm: 1	post chemo +ln/total: 8/21	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508122/suppl/GSM508122_29539_AB01833935_35648.CEL.gz	22283	Reanalyzed by: GSE205568	73	Pass	7-21-04	2	0	-20.9477887370504	P	100	N/A	N/A	N	IDC	RD	8/21	1	N	N/A	1	4	Taxol x 12 FAC x 4	H	2	2-21-05	MRM	2
GSM508123	breast cancer 323	GSM508123	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -27.1437355341295	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-4-03	age: 40	race: H	histology: IDC	prechemo t: 1	prechemo n: 1	bmn grade: 3	er% positive: 50	er status: P	pr% positive: 50	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: FAC x 3 (d/t P.D) Taxol x 12	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 5-20-04	post chemo size cm: 1.6	post chemo +ln/total: 9/22	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508123/suppl/GSM508123_U133A_FL42-323_07_07_05.CEL.gz	22283	Reanalyzed by: GSE205568	40	Pass	11-4-03	3	0	-27.1437355341295	P	50	N/A	0	N	IDC	RD	9/22	1.6	P	50	1	1	FAC x 3 (d/t P.D) Taxol x 12	H	1	5-20-04	MRM	2
GSM508124	breast cancer 343	GSM508124	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -20.1749385955918	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-20-03	age: 49	race: A	histology: IDC	prechemo t: 2	prechemo n: 3	bmn grade: 2	er% positive: 90	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: 2	her 2 fish: 0.86	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 8-16-04	post chemo size cm: 1.7	post chemo +ln/total: 6/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508124/suppl/GSM508124_29539_AB01833542_35683.CEL.gz	22283	Reanalyzed by: GSE205568	49	Pass	11-20-03	2	0	-20.1749385955918	P	90	0.86	2	N	IDC	RD	6/18	1.7	P	90	3	2	Taxol x 12 FAC x 4	A	2	8-16-04	MRM	2
GSM508125	breast cancer 365	GSM508125	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -29.2089382715367	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 2-24-03	age: 42	race: W	histology: ILC	prechemo t: 2	prechemo n: 1	bmn grade: 1	er% positive: 90	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.02	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 9-13-04	post chemo size cm: 1.9	post chemo +ln/total: 11/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508125/suppl/GSM508125_U133A_80_FL_080_FL256-365_04_18_06.CEL.gz	22283	Reanalyzed by: GSE205568	42	Pass	2-24-03	1	0	-29.2089382715367	P	90	1.02	N/A	N	ILC	RD	11/18	1.9	P	90	1	2	Taxol x 12 FAC x 4	W	2	9-13-04	MRM	2
GSM508126	breast cancer 385	GSM508126	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -20.9625355486605	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 3-30-04	age: 65	race: W	histology: IDC	prechemo t: 1	prechemo n: 1	bmn grade: 2	er% positive: 100	er status: P	pr% positive: 60	pr status: P	her 2 status: P	her 2 ihc: 2	her 2 fish: 2.67	preoperative treatment: FEC x 3 ( d/t N.C)Taxol x 12	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 10-22-04	post chemo size cm: 2	post chemo +ln/total: 1/12	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508126/suppl/GSM508126_U133A_FL58-385_07_27_05.CEL.gz	22283	Reanalyzed by: GSE205568	65	Pass	3-30-04	2	0	-20.9625355486605	P	100	2.67	2	P	IDC	RD	1/12	2	P	60	1	1	FEC x 3 ( d/t N.C)Taxol x 12	W	1	10-22-04	MRM	2
GSM508127	breast cancer PERU12-14	GSM508127	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -17.3847318633798	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-5-05	age: 65	race: H	histology: IDC	prechemo t: 2	prechemo n: 2	bmn grade: 3	er% positive: 95	er status: P	pr% positive: 70	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 8-1-05	post chemo size cm: 2	post chemo +ln/total: 2/25	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508127/suppl/GSM508127_29539_AB01833741_35650.CEL.gz	22283	Reanalyzed by: GSE205568	65	Pass	1-5-05	3	0	-17.3847318633798	P	95	N/A	N/A	N	IDC	RD	2/25	2	P	70	2	2	Taxol x 12 FAC x 4	H	2	8-1-05	MRM	2
GSM508128	breast cancer 107	GSM508128	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -37.7720128267774	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 6-27-00	age: 47	race: B	histology: IDC	prechemo t: 3	prechemo n: 1	bmn grade: 2	er% positive: 90	er status: P	pr% positive: 10	pr status: P	her 2 status: N	her 2 ihc: 2	her 2 fish: 1.27	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 2-12-01	post chemo size cm: 2.2	post chemo +ln/total: 1/31	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508128/suppl/GSM508128_29539_AB01833535_35695.CEL.gz	22283	Reanalyzed by: GSE205568	47	Pass	6-27-00	2	0	-37.7720128267774	P	90	1.27	2	N	IDC	RD	1/31	2.2	P	10	1	3	Taxol x 12 FAC x 4	B	2	2-12-01	MRM	2
GSM508129	breast cancer 315	GSM508129	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -13.3378603057117	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 10-8-03	age: 36	race: W	histology: IDC/ILC	prechemo t: 2	prechemo n: 1	bmn grade: 2	er% positive: 100	er status: P	pr% positive: 100	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.02	preoperative treatment: Taxol x 7 (d/t N.C) FAC x 4    (Multifocal,  Declined hormonal therapy and XRT)	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 3-31-04	post chemo size cm: 3	post chemo +ln/total: 3/20	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508129/suppl/GSM508129_29539_AB01723032_35694.CEL.gz	22283	Reanalyzed by: GSE205568	36	Pass	10-8-03	2	0	-13.3378603057117	P	100	1.02	N/A	N	IDC/ILC	RD	3/20	3	P	100	1	2	Taxol x 7 (d/t N.C) FAC x 4    (Multifocal,  Declined hormonal therapy and XRT)	W	2	3-31-04	MRM	2
GSM508130	breast cancer 399	GSM508130	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 13.3397398649558	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 4-19-04	age: 40	race: W	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 2	er% positive: 90	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: 1	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 12-21-04	post chemo size cm: 3	post chemo +ln/total: 3/24	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508130/suppl/GSM508130_29539_AB01723039_35684.CEL.gz	22283	Reanalyzed by: GSE205568	40	Pass	4-19-04	2	1	13.3397398649558	P	90	1	1	N	IDC	RD	3/24	3	P	90	1	2	Taxol x 12 FAC x 4	W	2	12-21-04	MRM	2
GSM508131	breast cancer 374	GSM508131	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -15.6030741844588	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-29-04	age: 53	race: H	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 1	her 2 fish: 1.35	preoperative treatment: Adriamycin x 6 Cyclophosphamide x 6 Taxol x 12	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 1	surgery type: MRM	surgery date: 11-8-04	post chemo size cm: 3.3	post chemo +ln/total: 1/15	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508131/suppl/GSM508131_U133A_80-FL-204-FL368-374_08_25_06.CEL.gz	22283	Reanalyzed by: GSE205568	53	Pass	1-29-04	3	0	-15.6030741844588	N	0	1.35	1	N	IDC	RD	1/15	3.3	N	0	0	2	Adriamycin x 6 Cyclophosphamide x 6 Taxol x 12	H	1	11-8-04	MRM	2
GSM508132	breast cancer 647	GSM508132	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -16.3727988159226	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 10-20-05	age: 65	race: W	histology: IDC	prechemo t: 3	prechemo n: 1	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 2	her 2 fish: 0.93	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 5-4-06	post chemo size cm: 5	post chemo +ln/total: 1/38	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508132/suppl/GSM508132_FL688-647.CEL.gz	22283	Reanalyzed by: GSE205568	65	Pass	10-20-05	3	0	-16.3727988159226	N	0	0.93	2	N	IDC	RD	1/38	5	N	0	1	3	Taxol x 12 FAC x 4	W	2	5-4-06	MRM	2
GSM508133	breast cancer 384	GSM508133	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -7.39708232747216	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 4-8-04	age: 60	race: H	histology: ILC	prechemo t: 3	prechemo n: 0	bmn grade: 2	er% positive: 50	er status: P	pr% positive: 40	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.05	preoperative treatment: Taxol x 12 FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 10-29-04	post chemo size cm: 8	post chemo +ln/total: 0/21	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508133/suppl/GSM508133_29539_AB01833747_35697.CEL.gz	22283	Reanalyzed by: GSE205568	60	Pass	4-8-04	2	0	-7.39708232747216	P	50	1.05	N/A	N	ILC	RD	0/21	8	P	40	0	3	Taxol x 12 FEC x 4	H	2	10-29-04	MRM	2
GSM508134	breast cancer 588	GSM508134	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -27.9588241540423	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 5-25-05	age: 43	race: B	histology: IDC	prechemo t: 4	prechemo n: 3	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: 0	preoperative treatment: Taxol x 8 (d/t P.D) FEC x 6 (P.D) XRT+ Xeloda	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 3-31-06	post chemo size cm: 12.5	post chemo +ln/total: 0/15	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508134/suppl/GSM508134_FL1000_588.CEL.gz	22283	Reanalyzed by: GSE205568	43	Pass	5-25-05	3	0	-27.9588241540423	N	0	0	N/A	N	IDC	RD	0/15	12.5	N	0	3	4	Taxol x 8 (d/t P.D) FEC x 6 (P.D) XRT+ Xeloda	B	2	3-31-06	MRM	2
GSM508135	breast cancer PERU17-19	GSM508135	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 15.6194300008465	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 2-2-05	age: 37	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: 3	er% positive: 40	er status: P	pr% positive: N/A	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 9-26-05	post chemo size cm: N/A	post chemo +ln/total: 21/21	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508135/suppl/GSM508135_29539_AB01722998_35652.CEL.gz	22283	Reanalyzed by: GSE205568	37	Pass	2-2-05	3	1	15.6194300008465	P	40	N/A	3	P	IDC	RD	21/21	N/A	N	N/A	2	4	Taxol x 12 FAC x 4	H	2	9-26-05	MRM	2
GSM508136	breast cancer PERU37	GSM508136	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -2.35711924688439	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-23-05	age: 48	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: 2	er% positive: 10	er status: P	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM	surgery date: 6-22-06	post chemo size cm: residual cancer	post chemo +ln/total: N/A	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508136/suppl/GSM508136_FL695-Peru37.CEL.gz	22283	Reanalyzed by: GSE205568	48	Pass	9-23-05	2	0	-2.35711924688439	P	10	N/A	N/A	N	IDC	RD	N/A	residual cancer	N	N/A	2	4	Taxol x 12 FAC x 4	H	2	6-22-06	MRM	2
GSM508137	breast cancer PERU23	GSM508137	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 13.9095275278196	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 7-8-05	age: 53	race: H	histology: IDC	prechemo t: 4	prechemo n: 0	bmn grade: N/A	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM/ALND	surgery date: 5-30-06	post chemo size cm: 0	post chemo +ln/total: 0/7	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508137/suppl/GSM508137_U133A_80_FL_087_FL263-PERU23_04_27_06.CEL.gz	22283	Reanalyzed by: GSE205568	53	Pass	7-8-05	N/A	1	13.9095275278196	N	N/A	N/A	N/A	N	IDC	pCR	0/7	0	N	N/A	0	4	Taxol x 12 FAC x 4	H	2	5-30-06	MRM/ALND	2
GSM508138	breast cancer PERU52	GSM508138	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 11.62821911643	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 12-16-05	age: 58	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: N/A	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM/ALND	surgery date: 7-11-06	post chemo size cm: 0	post chemo +ln/total: 0/13	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508138/suppl/GSM508138_FL727-peru52.CEL.gz	22283	Reanalyzed by: GSE205568	58	Pass	12-16-05	N/A	1	11.62821911643	N	N/A	N/A	N/A	N	IDC	pCR	0/13	0	N	N/A	1	4	Taxol x 12 FAC x 4	H	2	7-11-06	MRM/ALND	2
GSM508139	breast cancer 673	GSM508139	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -1.63797341845566	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 12-6-05	age: 58	race: W	histology: IDC	prechemo t: 2	prechemo n: 3	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	preoperative treatment: Taxol x 11 ( one dose missed & no repleced) FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM/ALND	surgery date: 8-1-06	post chemo size cm: 1.5	post chemo +ln/total: 17/30		N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508139/suppl/GSM508139_FL689-673.CEL.gz	22283	Reanalyzed by: GSE205568	58	Pass	12-6-05	3	0	-1.63797341845566	N	0	NA	0	N	IDC	RD	17/30	1.5	N	0	3	2	Taxol x 11 ( one dose missed & no repleced) FEC x 4	W	2	8-1-06	MRM/ALND	2
GSM508140	breast cancer PERU26	GSM508140	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -0.225886509797419	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 6-20-05	age: 66	race: H	histology: IDC	prechemo t: 2	prechemo n: 2	bmn grade: 2	er% positive: 80	er status: P	pr% positive: 10	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM/ALND	surgery date: 6-13-06	post chemo size cm: N/A	post chemo +ln/total: 10/13	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508140/suppl/GSM508140_FL694-Peru26.CEL.gz	22283	Reanalyzed by: GSE205568	66	Pass	6-20-05	2	0	-0.225886509797419	P	80	N/A	N/A	N	IDC	RD	10/13	N/A	P	10	2	2	Taxol x 12 FAC x 4	H	2	6-13-06	MRM/ALND	2
GSM508141	breast cancer MEXICO3	GSM508141	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -20.1543321409554	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 7-3-04	age: 53	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: N/A	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol x 12    FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM/ALND	surgery date: 5-11-05	post chemo size cm: N/A	post chemo +ln/total: 1/14	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508141/suppl/GSM508141_U133A_80-FL-123_FL230-GM3_05_25_06.CEL.gz	22283	Reanalyzed by: GSE205568	53	Pass	7-3-04	N/A	0	-20.1543321409554	N	0	N/A	0	N	IDC	RD	1/14	N/A	N	0	2	4	Taxol x 12    FEC x 4	H	2	5-11-05	MRM/ALND	2
GSM508142	breast cancer PERU28	GSM508142	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -29.2402929264972	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 8-17-05	age: 39	race: H	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 2	er% positive: 80	er status: P	pr% positive: 50	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM/ALND	surgery date: 6-17-06	post chemo size cm: N/A	post chemo +ln/total: 11/15	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508142/suppl/GSM508142_U133A_80-FL-091_FL267-Peru28_05_09_06.CEL.gz	22283	Reanalyzed by: GSE205568	39	Pass	8-17-05	2	0	-29.2402929264972	P	80	N/A	N/A	N	IDC	RD	11/15	N/A	P	50	1	2	Taxol x 12 FAC x 4	H	2	6-17-06	MRM/ALND	2
GSM508143	breast cancer PERU66	GSM508143	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -47.4782228200856	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 2-24-06	age: 48	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: 2	er% positive: 80	er status: P	pr% positive: 60	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM/ALND	surgery date: 10-14-06	post chemo size cm: N/A	post chemo +ln/total: 5/16	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508143/suppl/GSM508143_FL731-Peru66.CEL.gz	22283	Reanalyzed by: GSE205568	48	Pass	2-24-06	2	0	-47.4782228200856	P	80	N/A	N/A	N	IDC	RD	5/16	N/A	P	60	1	4	Taxol x 12 FAC x 4	H	2	10-14-06	MRM/ALND	2
GSM508144	breast cancer PERU48	GSM508144	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -25.1739426426593	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 10-28-05	age: 59	race: H	histology: IDC	prechemo t: 4	prechemo n: 3	bmn grade: 2	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM/ALND	surgery date: 5-27-06	post chemo size cm: N/A	post chemo +ln/total: 14/16	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508144/suppl/GSM508144_FL697-Peru48.CEL.gz	22283	Reanalyzed by: GSE205568	59	Pass	10-28-05	2	0	-25.1739426426593	N	N/A	N/A	N/A	N	IDC	RD	14/16	N/A	N	N/A	3	4	Taxol x 12 FAC x 4	H	2	5-27-06	MRM/ALND	2
GSM508145	breast cancer PERU42	GSM508145	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -18.2191474964111	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-23-05	age: 42	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: N/A	er% positive: 95	er status: P	pr% positive: 80	pr status: P	her 2 status: N	her 2 ihc: 2	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM/ALND	surgery date: 5-9-06	post chemo size cm: N/A	post chemo +ln/total: 1/21	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508145/suppl/GSM508145_FL699-PERU42.CEL.gz	22283	Reanalyzed by: GSE205568	42	Pass	9-23-05	N/A	0	-18.2191474964111	P	95	N/A	2	N	IDC	RD	1/21	N/A	P	80	2	4	Taxol x 12 FAC x 4	H	2	5-9-06	MRM/ALND	2
GSM508146	breast cancer PERU54	GSM508146	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 14.0377316131671	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 12-19-05	age: 63	race: H	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: N/A	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM/ALND	surgery date: 8-1-06	post chemo size cm: N/A	post chemo +ln/total: 12/16	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508146/suppl/GSM508146_FL728-peru54.CEL.gz	22283	Reanalyzed by: GSE205568	63	Pass	12-19-05	N/A	1	14.0377316131671	N	N/A	N/A	N/A	N	IDC	RD	12/16	N/A	N	N/A	1	2	Taxol x 12 FAC x 4	H	2	8-1-06	MRM/ALND	2
GSM508147	breast cancer PERU40	GSM508147	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 12.6339013711586	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 9-23-05	age: 40	race: H	histology: IDC	prechemo t: 3	prechemo n: 1	bmn grade: 3	er% positive: 70	er status: P	pr% positive: 80	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM/ALND	surgery date: 5-9-06	post chemo size cm: residual cancer	post chemo +ln/total: 0/10	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508147/suppl/GSM508147_U133A_80-FL-226-FL390-PERU40_09_22_06.CEL.gz	22283	Reanalyzed by: GSE205568	40	Pass	9-23-05	3	1	12.6339013711586	P	70	N/A	N/A	N	IDC	RD	0/10	residual cancer	P	80	1	3	Taxol x 12 FAC x 4	H	2	5-9-06	MRM/ALND	2
GSM508148	breast cancer PERU74	GSM508148	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 2.55877585924463	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 4-26-06	age: 50	race: H	histology: IDC	prechemo t: 3	prechemo n: 1	bmn grade: 3	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM/ALND	surgery date: 2-1-07	post chemo size cm: residual cancer	post chemo +ln/total: 0/24	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508148/suppl/GSM508148_FL733-Peru74.CEL.gz	22283	Reanalyzed by: GSE205568	50	Pass	4-26-06	3	1	2.55877585924463	N	N/A	N/A	3	P	IDC	RD	0/24	residual cancer	N	N/A	1	3	Taxol x 12 FAC x 4	H	2	2-1-07	MRM/ALND	2
GSM508149	breast cancer LBJ047	GSM508149	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: -0.617024752396901	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 10-15-04	age: 46	race: H	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 75	er status: P	pr% positive: 75	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol  x 12  FAC   x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: MRM/LNB	surgery date: 6-9-05	post chemo size cm: 0	post chemo +ln/total: 0/2	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508149/suppl/GSM508149_U133A_80-FL-104_FL280-LBJ47_05_17_06.CEL.gz	22283	Reanalyzed by: GSE205568	46	Pass	10-15-04	3	0	-0.617024752396901	P	75	N/A	0	N	IDC	pCR	0/2	0	P	75	0	2	Taxol  x 12  FAC   x 4	H	2	6-9-05	MRM/LNB	2
GSM508150	breast cancer MEXICO11	GSM508150	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: -23.5713337902653	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 6-16-05	age: 45	race: H	histology: ILC	prechemo t: 2	prechemo n: 0	bmn grade: N/A	er% positive: N/A	er status: P	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol x 12   FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: N/A	surgery date: 1-21-06	post chemo size cm: 0	post chemo +ln/total: 0/26	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508150/suppl/GSM508150_U133A_80-FL-127_FL234-GM11_05_25_06.CEL.gz	22283	Reanalyzed by: GSE205568	45	Pass	6-16-05	N/A	0	-23.5713337902653	P	N/A	N/A	0	N	ILC	pCR	0/26	0	N	0	0	2	Taxol x 12   FEC x 4	H	2	1-21-06	N/A	2
GSM508151	breast cancer MEXICO14	GSM508151	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 0.777270735630736	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 8-8-05	age: 64	race: H	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: N/A	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: N/A	preoperative treatment: Taxol x12   FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: N/A	surgery date: 4-19-06	post chemo size cm: 0	post chemo +ln/total: 0/6	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508151/suppl/GSM508151_U133A_80-FL-128_FL235-GM14_05_25_06.CEL.gz	22283	Reanalyzed by: GSE205568	64	Pass	8-8-05	N/A	1	0.777270735630736	N	0	N/A	3	P	IDC	pCR	0/6	0	N	0	0	2	Taxol x12   FEC x 4	H	2	4-19-06	N/A	2
GSM508152	breast cancer MEXICO17	GSM508152	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 12.3507508079056	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 9-6-05	age: 49	race: H	histology: IDC	prechemo t: 3	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol x 12 FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: N/A	surgery date: 5-12-06	post chemo size cm: 0	post chemo +ln/total: 0/14	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508152/suppl/GSM508152_FL692-GM17.CEL.gz	22283	Reanalyzed by: GSE205568	49	Pass	9-6-05	3	1	12.3507508079056	N	0	N/A	0	N	IDC	pCR	0/14	0	N	0	0	3	Taxol x 12 FEC x 4	H	2	5-12-06	N/A	2
GSM508153	breast cancer MEXICO1	GSM508153	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -18.2489054499692	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 8-30-04	age: 37	race: H	histology: IDC	prechemo t: 3	prechemo n: 2	bmn grade: N/A	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol x 12    FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: N/A	surgery date: 6-10-05	post chemo size cm: N/A	post chemo +ln/total: 3/6	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508153/suppl/GSM508153_U133A_80-FL-122_FL299-GM1_05_25_06.CEL.gz	22283	Reanalyzed by: GSE205568	37	Pass	8-30-04	N/A	0	-18.2489054499692	N	0	N/A	0	N	IDC	RD	3/6	N/A	N	0	2	3	Taxol x 12    FEC x 4	H	2	6-10-05	N/A	2
GSM508154	breast cancer MEXICO5	GSM508154	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -15.711987309196	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 8-16-04	age: 61	race: H	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol x 12    FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: N/A	surgery date: 7-28-05	post chemo size cm: N/A	post chemo +ln/total: 6/10	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508154/suppl/GSM508154_U133A_80-FL-124_FL231-GM5_05_25_06.CEL.gz	22283	Reanalyzed by: GSE205568	61	Pass	8-16-04	3	0	-15.711987309196	N	0	N/A	0	N	IDC	RD	6/10	N/A	N	0	0	2	Taxol x 12    FEC x 4	H	2	7-28-05	N/A	2
GSM508155	breast cancer MEXICO7	GSM508155	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -38.1682086432593	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 5-5-05	age: 61	race: H	histology: IDC	prechemo t: 2	prechemo n: 2	bmn grade: 3	er% positive: N/A	er status: P	pr% positive: N/A	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: N/A	preoperative treatment: Taxol x 12    FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: N/A	surgery date: 12-6-05	post chemo size cm: N/A	post chemo +ln/total: 3/15	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508155/suppl/GSM508155_U133A_80-FL-126_FL233-GM7_05_25_06.CEL.gz	22283	Reanalyzed by: GSE205568	61	Pass	5-5-05	3	0	-38.1682086432593	P	N/A	N/A	1	N	IDC	RD	3/15	N/A	P	N/A	2	2	Taxol x 12    FEC x 4	H	2	12-6-05	N/A	2
GSM508156	breast cancer MEXICO6	GSM508156	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 8.50430720662553	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 3-1-05	age: 46	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: P	her 2 ihc: 2	her 2 fish: N/A	preoperative treatment: Taxol x 12    FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: N/A	surgery date: 10-4-05	post chemo size cm: N/A	post chemo +ln/total: 18/20	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508156/suppl/GSM508156_U133A_80-FL-125_FL232-GM6_05_25_06.CEL.gz	22283	Reanalyzed by: GSE205568	46	Pass	3-1-05	3	1	8.50430720662553	N	0	N/A	2	P	IDC	RD	18/20	N/A	N	0	2	4	Taxol x 12    FEC x 4	H	2	10-4-05	N/A	2
GSM508157	breast cancer MEXICO16	GSM508157	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -6.91921591650316	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-19-05	age: 65	race: H	histology: IDC	prechemo t: 4	prechemo n: 0	bmn grade: N/A	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol x 12   FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: N/A	surgery date: 4-12-06	post chemo size cm: residual cancer	post chemo +ln/total: 0/15	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508157/suppl/GSM508157_U133A_80-FL-129_FL236-GM16_05_25_06.CEL.gz	22283	Reanalyzed by: GSE205568	65	Pass	9-19-05	N/A	0	-6.91921591650316	N	0	N/A	0	N	IDC	RD	0/15	residual cancer	N	0	0	4	Taxol x 12   FEC x 4	H	2	4-12-06	N/A	2
GSM508158	breast cancer PERU56	GSM508158	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -8.40180978299213	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 12-30-05	age: 44	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: N/A	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: ND	surgery date: ND	post chemo size cm: ND	post chemo +ln/total: ND	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508158/suppl/GSM508158_FL729-peru56.CEL.gz	22283	Reanalyzed by: GSE205568	44	Pass	12-30-05	N/A	0	-8.40180978299213	N	N/A	N/A	N/A	N	IDC	RD	ND	ND	N	N/A	2	4	Taxol x 12 FAC x 4	H	2	ND	ND	2
GSM508159	breast cancer LBJ046	GSM508159	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 12.8231319920797	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 10-20-04	age: 59	race: W	histology: IDC/IBC	prechemo t: 4	prechemo n: 2	bmn grade: 2	er% positive: 31	er status: P	pr% positive: 4	pr status: N	her 2 status: N	her 2 ihc: 2	her 2 fish: N/A	preoperative treatment: Taxol  x 12   FAC x  3 (D/T P.D)	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: ND	surgery date: ND	post chemo size cm: ND	post chemo +ln/total: ND	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508159/suppl/GSM508159_FL693-LBJ46.CEL.gz	22283	Reanalyzed by: GSE205568	59	Pass	10-20-04	2	1	12.8231319920797	P	31	N/A	2	N	IDC/IBC	RD	ND	ND	N	4	2	4	Taxol  x 12   FAC x  3 (D/T P.D)	W	2	ND	ND	2
GSM508160	breast cancer PERU31	GSM508160	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 32.5736036838734	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 8-26-05	age: 44	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: N/A	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: P	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 8  (D/T progression)	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: ND	surgery date: ND	post chemo size cm: ND	post chemo +ln/total: ND	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508160/suppl/GSM508160_U133A_80_FL_089_FL265-PERU31_04_27_06.CEL.gz	22283	Reanalyzed by: GSE205568	44	Pass	8-26-05	N/A	1	32.5736036838734	N	N/A	N/A	N/A	P	IDC	RD	ND	ND	N	N/A	1	4	Taxol x 8  (D/T progression)	H	2	ND	ND	2
GSM508161	breast cancer PERU60	GSM508161	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -16.7995173433137	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-25-06	age: 29	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: N/A	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 5   (Off protocol D/T progression)	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: ND for PD	surgery date: ND	post chemo size cm: ND	post chemo +ln/total: ND	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508161/suppl/GSM508161_FL1673_Peru60.CEL.gz	22283	Reanalyzed by: GSE205568	29	Pass	1-25-06	N/A	0	-16.7995173433137	N	N/A	N/A	N/A	N	IDC	RD	ND	ND	N	N/A	1	4	Taxol x 5   (Off protocol D/T progression)	H	2	ND	ND for PD	2
GSM508162	breast cancer PERU29	GSM508162	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 14.1471126254582	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 8-19-05	age: 55	race: H	histology: IDC	prechemo t: 3	prechemo n: 1	bmn grade: N/A	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: ND for PD and brain mets	surgery date: ND	post chemo size cm: ND	post chemo +ln/total: ND	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508162/suppl/GSM508162_U133A_80_FL_088_FL264-PERU29_04_27_06.CEL.gz	22283	Reanalyzed by: GSE205568	55	Pass	8-19-05	N/A	1	14.1471126254582	N	N/A	N/A	N/A	N	IDC	RD	ND	ND	N	N/A	1	3	Taxol x 12 FAC x 4	H	2	ND	ND for PD and brain mets	2
GSM508163	breast cancer PERU14-16	GSM508163	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 30.9072768459446	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 1-28-05	age: 58	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: 3	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4  (Progressed on Neoadjuvant Chemotherapy. Moved on to XRT. No surgery)	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: ND for PD and reccurrence	surgery date: ND	post chemo size cm: ND	post chemo +ln/total: ND	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508163/suppl/GSM508163_29539_AB01723030_35657.CEL.gz	22283	Reanalyzed by: GSE205568	58	Pass	1-28-05	3	1	30.9072768459446	N	N/A	N/A	N/A	N	IDC	RD	ND	ND	N	N/A	2	4	Taxol x 12 FAC x 4  (Progressed on Neoadjuvant Chemotherapy. Moved on to XRT. No surgery)	H	2	ND	ND for PD and reccurrence	2
GSM508164	breast cancer SPAIN55	GSM508164	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: -5.31143690176941	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 3-20-06	age: 48	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 3	prechemo n: 1	bmn grade: 3	er% positive: 25	er status: P	pr% positive: 40	pr status: P	her 2 status: P	her 2 ihc: 3	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Quadrantectomy	surgery date: 9-19-06	post chemo size cm: 0	post chemo +ln/total: 0/10	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508164/suppl/GSM508164_FL725-spain55.CEL.gz	22283	Reanalyzed by: GSE205568	48	Pass	3-20-06	3	0	-5.31143690176941	P	25	ND	3	P	Infiltrating Ductal Carcinoma	pCR	0/10	0	P	40	1	3	Paclitaxel x(12 )  + FEC x(4 )	W	2	9-19-06	Quadrantectomy	2
GSM508165	breast cancer SPAIN3	GSM508165	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 11.7553429030741	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 7-29-05	age: 45	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: P	her 2 ihc: 3	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Quadrantectomy	surgery date: 2-27-06	post chemo size cm: 0	post chemo +ln/total: 0/14	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508165/suppl/GSM508165_FL843-Spain3.CEL.gz	22283	Reanalyzed by: GSE205568	45	Pass	7-29-05	3	1	11.7553429030741	N	0	ND	3	P	Infiltrating Ductal Carcinoma	pCR	0/14	0	N	0	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	2-27-06	Quadrantectomy	2
GSM508166	breast cancer SPAIN51	GSM508166	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -9.79336831216278	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 3-14-06	age: 44	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 3	prechemo n: 1	bmn grade: 1	er% positive: 0	er status: N	pr% positive: 25-50	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Quadrantectomy	surgery date: 6-9-06	post chemo size cm: 1.3	post chemo +ln/total: 4/6	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508166/suppl/GSM508166_FL854-Spain51.CEL.gz	22283	Reanalyzed by: GSE205568	44	Pass	3-14-06	1	0	-9.79336831216278	N	0	ND	0	N	Infiltrating Ductal Carcinoma	RD	4/6	1.3	P	25-50	1	3	Paclitaxel x(12 )  + FEC x(4 )	W	2	6-9-06	Quadrantectomy	2
GSM508167	breast cancer SPAIN12	GSM508167	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -21.4620293741718	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-23-05	age: 61	race: W	histology: Inflitrating Lobular Carcinoma	prechemo t: 2	prechemo n: 0	bmn grade: 1	er% positive: 90	er status: P	pr% positive: 60	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Quadrantectomy	surgery date: 7-3-06	post chemo size cm: 1.5	post chemo +ln/total: 1/11	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508167/suppl/GSM508167_FL846-Spain12.CEL.gz	22283	Reanalyzed by: GSE205568	61	Pass	9-23-05	1	0	-21.4620293741718	P	90	ND	0	N	Inflitrating Lobular Carcinoma	RD	1/11	1.5	P	60	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	7-3-06	Quadrantectomy	2
GSM508168	breast cancer SPAIN6	GSM508168	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -29.3518905603978	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 9-9-05	age: 67	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 95	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: 2	her 2 fish: ND	preoperative treatment: Paclitaxel x(12 )  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Quadrantectomy	surgery date: 6-3-06	post chemo size cm: 2.8	post chemo +ln/total: 0/20	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508168/suppl/GSM508168_FL845-Spain6.CEL.gz	22283	Reanalyzed by: GSE205568	67	Pass	9-9-05	2	0	-29.3518905603978	P	95	ND	2	N	Infiltrating Ductal Carcinoma	RD	0/20	2.8	P	90	0	2	Paclitaxel x(12 )  + FEC x(4 )	W	2	6-3-06	Quadrantectomy	2
GSM508169	breast cancer SPAIN41	GSM508169	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -7.81322023398025	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 2-17-06	age: 64	race: W	histology: Infiltrating Ductal Carcinoma	prechemo t: 3	prechemo n: 1	bmn grade: 3	er% positive: 25-50	er status: P	pr% positive: 25	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: ND	preoperative treatment: Paclitaxel x( 12)  + FEC x(4 )	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: Quadrantectomy both breasts	surgery date: 9-13-06	post chemo size cm: 1.3	post chemo +ln/total: 0/11	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508169/suppl/GSM508169_FL852-Spain41.CEL.gz	22283	Reanalyzed by: GSE205568	64	Pass	2-17-06	3	0	-7.81322023398025	P	25-50	ND	0	N	Infiltrating Ductal Carcinoma	RD	0/11	1.3	P	25	1	3	Paclitaxel x( 12)  + FEC x(4 )	W	2	9-13-06	Quadrantectomy both breasts	2
GSM508170	breast cancer 321	GSM508170	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: -24.8525322185487	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 10-31-03	age: 53	race: W	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 2	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 2	her 2 fish: 1.3	preoperative treatment: Taxol x 12 FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: SM	surgery date: 6-16-04	post chemo size cm: 0	post chemo +ln/total: 0/21	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508170/suppl/GSM508170_FL1289_321.CEL.gz	22283	Reanalyzed by: GSE205568	53	Pass	10-31-03	2	0	-24.8525322185487	N	0	1.3	2	N	IDC	pCR	0/21	0	N	0	1	2	Taxol x 12 FEC x 4	W	2	6-16-04	SM	2
GSM508171	breast cancer 382	GSM508171	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 17.6150587037082	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 3-15-04	age: 55	race: B	histology: IDC	prechemo t: 2	prechemo n: 3	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: P	her 2 ihc: N/A	her 2 fish: 10.36	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: SM	surgery date: 11-23-04	post chemo size cm: 0	post chemo +ln/total: 0/13	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508171/suppl/GSM508171_U133A_80_FL_090_FL266-382_04_27_06.CEL.gz	22283	Reanalyzed by: GSE205568	55	Pass	3-15-04	3	1	17.6150587037082	N	0	10.36	N/A	P	IDC	pCR	0/13	0	N	0	3	2	Taxol x 12 FAC x 4	B	2	11-23-04	SM	2
GSM508172	breast cancer 447	GSM508172	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -7.9486003011516	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 6-10-04	age: 44	race: B	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 95	er status: P	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.63	preoperative treatment: Taxol x 12 FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: SM	surgery date: 3-7-05	post chemo size cm: 2.5	post chemo +ln/total: 0/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508172/suppl/GSM508172_29539_AB01723044_35687.CEL.gz	22283	Reanalyzed by: GSE205568	44	Pass	6-10-04	2	0	-7.9486003011516	P	95	1.63	N/A	N	IDC	RD	0/18	2.5	N	0	0	2	Taxol x 12 FEC x 4	B	2	3-7-05	SM	2
GSM508173	breast cancer 513	GSM508173	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 9.73002599636311	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 12-14-04	age: 59	race: B	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 1	her 2 fish: 0.96	preoperative treatment: FAC x 4(d/t N.C) Taxol x 6 (d/t severe Fatigue) (FAC resistance & pCR at the end)	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 1	surgery type: SM/ALND	surgery date: 6-16-05	post chemo size cm: 0	post chemo +ln/total: 0/20	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508173/suppl/GSM508173_FL491-513.CEL.gz	22283	Reanalyzed by: GSE205568	59	Pass	12-14-04	3	1	9.73002599636311	N	0	0.96	1	N	IDC	pCR	0/20	0	N	0	1	2	FAC x 4(d/t N.C) Taxol x 6 (d/t severe Fatigue) (FAC resistance & pCR at the end)	B	1	6-16-05	SM/ALND	2
GSM508174	breast cancer 625	GSM508174	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: 20.1497779240399	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 7-21-05	age: 49	race: W	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.12	preoperative treatment: Taxol x 12 FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: SM/ALND	surgery date: 4-12-06	post chemo size cm: 0	post chemo +ln/total: 0/20	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508174/suppl/GSM508174_U133A_80-FL-096_FL272-625_05_11_06.CEL.gz	22283	Reanalyzed by: GSE205568	49	Pass	7-21-05	3	1	20.1497779240399	N	0	1.12	N/A	N	IDC	pCR	0/20	0	N	0	1	2	Taxol x 12 FEC x 4	W	2	4-12-06	SM/ALND	2
GSM508175	breast cancer 340	GSM508175	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -37.8485189262246	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 11-20-03	age: 54	race: H	histology: IDC	prechemo t: 4	prechemo n: 1	bmn grade: 2	er% positive: 100	er status: P	pr% positive: 4.9	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: 0.88	preoperative treatment: FAC x 6 Taxol x 12	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 1	surgery type: SM/ALND	surgery date: 11-5-04	post chemo size cm: 0	post chemo +ln/total: 2/20	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508175/suppl/GSM508175_FL489-340.CEL.gz	22283	Reanalyzed by: GSE205568	54	Pass	11-20-03	2	0	-37.8485189262246	P	100	0.88	N/A	N	IDC	RD	2/20	0	N	4.9	1	4	FAC x 6 Taxol x 12	H	1	11-5-04	SM/ALND	2
GSM508176	breast cancer 545	GSM508176	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -2.29653531499207	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 2-8-05	age: 58	race: B	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 2	her 2 fish: 1.08	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: SM/ALND	surgery date: 9-1-05	post chemo size cm: 2.3	post chemo +ln/total: 1/12	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508176/suppl/GSM508176_FL501-545.CEL.gz	22283	Reanalyzed by: GSE205568	58	Pass	2-8-05	3	0	-2.29653531499207	N	0	1.08	2	N	IDC	RD	1/12	2.3	N	0	1	2	Taxol x 12 FAC x 4	B	2	9-1-05	SM/ALND	2
GSM508177	breast cancer LBJ054	GSM508177	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -16.5350881468767	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-26-05	age: 35	race: H	histology: IDC	prechemo t: 1	prechemo n: 1	bmn grade: 2	er% positive: 100	er status: P	pr% positive: 100	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: SM/ALND	surgery date: 8-10-05	post chemo size cm: 2.5	post chemo +ln/total: 6/7	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508177/suppl/GSM508177_U133A_80-FL-098_FL274-LBJ54_05_11_06.CEL.gz	22283	Reanalyzed by: GSE205568	35	Pass	1-26-05	2	0	-16.5350881468767	P	100	N/A	0	N	IDC	RD	6/7	2.5	P	100	1	1	Taxol x 12 FAC x 4	H	2	8-10-05	SM/ALND	2
GSM508178	breast cancer PERU76	GSM508178	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 4.71805823198156	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 5-22-06	age: 51	race: H	histology: IDC	prechemo t: 4	prechemo n: 2	bmn grade: N/A	er% positive: N/A	er status: N	pr% positive: N/A	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: N/A	preoperative treatment: Taxol x 12 FAC x  4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: SM/ALND	surgery date: 12-21-06	post chemo size cm: N/A	post chemo +ln/total: 3/10	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508178/suppl/GSM508178_FL698-PERU76.CEL.gz	22283	Reanalyzed by: GSE205568	51	Pass	5-22-06	N/A	1	4.71805823198156	N	N/A	N/A	N/A	N	IDC	RD	3/10	N/A	N	N/A	2	4	Taxol x 12 FAC x  4	H	2	12-21-06	SM/ALND	2
GSM508179	breast cancer LBJ082	GSM508179	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: pCR	array qc: Pass	dlda30 score: -0.173643125583112	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 10-26-05	age: 39	race: B	histology: IDC	prechemo t: 3	prechemo n: 1	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol  x  12  FAC x  4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: SM/LNB	surgery date: 6-30-06	post chemo size cm: 0	post chemo +ln/total: 0/2	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508179/suppl/GSM508179_FL842-LBJ82.CEL.gz	22283	Reanalyzed by: GSE205568	39	Pass	10-26-05	3	0	-0.173643125583112	N	0	N/A	0	N	IDC	pCR	0/2	0	N	0	1	3	Taxol  x  12  FAC x  4	B	2	6-30-06	SM/LNB	2
GSM508180	breast cancer 319	GSM508180	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -29.6572204222266	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 10-23-03	age: 26	race: W	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 95	er status: P	pr% positive: 95	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: 0.92	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 1	surgery type: SM/LNB	surgery date: 4-29-04	post chemo size cm: 0.8	post chemo +ln/total: 0/4	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508180/suppl/GSM508180_FL645-319.CEL.gz	22283	Reanalyzed by: GSE205568	26	Pass	10-23-03	2	0	-29.6572204222266	P	95	0.92	N/A	N	IDC	RD	0/4	0.8	P	95	0	2	Taxol x 12 FAC x 4	W	1	4-29-04	SM/LNB	2
GSM508181	breast cancer LBJ070	GSM508181	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 3.77721287385066	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 5-18-05	age: 38	race: H	histology: IDC	prechemo t: 3	prechemo n: 0	bmn grade: 3	er% positive: 100	er status: P	pr% positive: 40	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol   x  12  FAC  x  4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: SM/LNB	surgery date: 3-3-06	post chemo size cm: 1	post chemo +ln/total: 0/1	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508181/suppl/GSM508181_U133A_80-FL-105_FL281-LBJ70_05_17_06.CEL.gz	22283	Reanalyzed by: GSE205568	38	Pass	5-18-05	3	1	3.77721287385066	P	100	N/A	0	N	IDC	RD	0/1	1	P	40	0	3	Taxol   x  12  FAC  x  4	H	2	3-3-06	SM/LNB	2
GSM508182	breast cancer 718	GSM508182	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 6.47994101440418	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 3-15-06	age: 36	race: W	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 3	er% positive: 0	er status: N	pr% positive: 9	pr status: N	her 2 status: N	her 2 ihc: 2	her 2 fish: 1.32	preoperative treatment: Taxol x 12 FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: SM/LNB	surgery date: 11-17-06	post chemo size cm: 1.5	post chemo +ln/total: 0/2	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508182/suppl/GSM508182_FL610-718.CEL.gz	22283	Reanalyzed by: GSE205568	36	Pass	3-15-06	3	1	6.47994101440418	N	0	1.32	2	N	IDC	RD	0/2	1.5	N	9	0	2	Taxol x 12 FEC x 4	W	2	11-17-06	SM/LNB	2
GSM508183	breast cancer 657	GSM508183	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: 0.886886668757143	dlda30 pred (1=pcr, 0=rd): 1	biopsy date mmddyy: 10-20-05	age: 48	race: H	histology: IDC	prechemo t: 1	prechemo n: 0	bmn grade: 2	er% positive: 0	er status: N	pr% positive: 10	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: 0.96	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: SM/LNB	surgery date: 6-8-06	post chemo size cm: 3	post chemo +ln/total: 0/5	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508183/suppl/GSM508183_FL756-657.CEL.gz	22283	Reanalyzed by: GSE205568	48	Pass	10-20-05	2	1	0.886886668757143	N	0	0.96	1	N	IDC	RD	0/5	3	P	10	0	1	Taxol x 12 FAC x 4	H	2	6-8-06	SM/LNB	2
GSM508184	breast cancer 690	GSM508184	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -23.2511163324434	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 1-26-06	age: 73	race: W	histology: IDC	prechemo t: 2	prechemo n: 1	bmn grade: 1	er% positive: 95	er status: P	pr% positive: 90	pr status: P	her 2 status: N	her 2 ihc: 1	her 2 fish: 0.86	preoperative treatment: Taxol x 12 FEC x4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: SM/LNB	surgery date: 8-15-06	post chemo size cm: 4	post chemo +ln/total: 14/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508184/suppl/GSM508184_FL561-690.CEL.gz	22283	Reanalyzed by: GSE205568	73	Pass	1-26-06	1	0	-23.2511163324434	P	95	0.86	1	N	IDC	RD	14/18	4	P	90	1	2	Taxol x 12 FEC x4	W	2	8-15-06	SM/LNB	2
GSM508185	breast cancer 710	GSM508185	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -19.530515779803	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 2-22-06	age: 53	race: W	histology: ILC/IDC	prechemo t: 2	prechemo n: 1	bmn grade: 2	er% positive: 100	er status: P	pr% positive: 50	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol x 12 FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: SM/LNB	surgery date: 12-20-06	post chemo size cm: 4.5	post chemo +ln/total: 0/1	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508185/suppl/GSM508185_FL682-710.CEL.gz	22283	Reanalyzed by: GSE205568	53	Pass	2-22-06	2	0	-19.530515779803	P	100	N/A	0	N	ILC/IDC	RD	0/1	4.5	P	50	1	2	Taxol x 12 FEC x 4	W	2	12-20-06	SM/LNB	2
GSM508186	breast cancer 685	GSM508186	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -47.2245318495388	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 12-21-05	age: 53	race: W	histology: IDC	prechemo t: 2	prechemo n: 0	bmn grade: 1	er% positive: 90	er status: P	pr% positive: 30	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: 0	preoperative treatment: Taxol x 12  FEC x4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: TM/ALND	surgery date: 8-15-06	post chemo size cm: 2.8	post chemo +ln/total: 2/9	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508186/suppl/GSM508186_FL787-685.CEL.gz	22283	Reanalyzed by: GSE205568	53	Pass	12-21-05	1	0	-47.2245318495388	P	90	0	N/A	N	IDC	RD	2/9	2.8	P	30	0	2	Taxol x 12  FEC x4	W	2	8-15-06	TM/ALND	2
GSM508187	breast cancer 746	GSM508187	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -35.6619323813975	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 5-26-06	age: 56	race: B	histology: ILC	prechemo t: 3	prechemo n: 0	bmn grade: 1	er% positive: 10	er status: P	pr% positive: 80	pr status: P	her 2 status: N	her 2 ihc: 0	her 2 fish: N/A	preoperative treatment: Taxol x 12 FEC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: TM/ALND	surgery date: 12-19-06	post chemo size cm: 8	post chemo +ln/total: 1/14	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508187/suppl/GSM508187_FL685-746.CEL.gz	22283	Reanalyzed by: GSE205568	56	Pass	5-26-06	1	0	-35.6619323813975	P	10	N/A	0	N	ILC	RD	1/14	8	P	80	0	3	Taxol x 12 FEC x 4	B	2	12-19-06	TM/ALND	2
GSM508188	breast cancer 502	GSM508188	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -17.3628171481123	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 10-25-04	age: 50	race: W	histology: IDC/ILC	prechemo t: 2	prechemo n: 0	bmn grade: 2	er% positive: 0	er status: N	pr% positive: 0	pr status: N	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.6	preoperative treatment: FEC x 3 (N.C) Taxol x 12	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 1	surgery type: TM/ALND	surgery date: 5-27-05	post chemo size cm: 10	post chemo +ln/total: 4/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508188/suppl/GSM508188_FL686-502.CEL.gz	22283	Reanalyzed by: GSE205568	50	Pass	10-25-04	2	0	-17.3628171481123	N	0	1.6	N/A	N	IDC/ILC	RD	4/18	10	N	0	0	2	FEC x 3 (N.C) Taxol x 12	W	1	5-27-05	TM/ALND	2
GSM508189	breast cancer 753	GSM508189	Public on Sep 15 2010	Feb 10 2010	Jun 06 2022	RNA	1	breast cancer FNA biopsy, pre-treatment	Homo sapiens	pcr or rd: RD	array qc: Pass	dlda30 score: -26.8492848143997	dlda30 pred (1=pcr, 0=rd): 0	biopsy date mmddyy: 6-16-06	age: 49	race: W	histology: IDC	prechemo t: 4	prechemo n: 0	bmn grade: 2	er% positive: 100	er status: P	pr% positive: 95	pr status: P	her 2 status: N	her 2 ihc: N/A	her 2 fish: 1.18	preoperative treatment: Taxol x 12 FAC x 4	treatment received (1=fac, 2=t/fac): 2	randomized (1=fac, 2=t/fac): 2	surgery type: TM/LNB	surgery date: 2-2-07	post chemo size cm: 2	post chemo +ln/total: 1/18	N/A	N/A	total RNA	total RNA was extracted from the FNA specimens using Qiagen RNeasy kit following the manufacturer’s instructions (http://www.qiagen.com).	biotin	Biotinylated cRNA were prepared according to the standard Affymetrix protocol from at least 1 ug total RNA using the BioArray High Yield RNA transcript labeling kit (Enzo Laboratories).	9606	Following fragmentation, 20 ug of cRNA were hybridized to affymetrix U133A arrays overnight at 42C. Microarrays were washed and stained in the Affymetrix Fluidics Station.	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000DX. This system is manufactured by Affymetrix Inc in Santa Clara, CA.	Gene expression data from breast cancer FNA biopsy, pre-treatment	The data were normalized using dChip version 1.3 followed by logrithm-base-10 transformation. The dChip version 1.3 was used to calculate Model Based Expression Index (MBEI) values of the arrays using the digital standard microarray MDA-BCNorm.CEL and the probe sensitivity index file UTMDACC-BreastCancerNormalizer.psi as described in Hess, et. al, Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and 5-Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer, Journal of Clinical Oncology, 24 (26), 2006.	GPL96	Yuan,,Qi	yqi1@mdanderson.org	Bioinformatics & Computational Biology	University of Texas M.D. Anderson Cancer Center	1400 Pressler St	Houston	TX	77030-4008	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM508nnn/GSM508189/suppl/GSM508189_FL701-753.CEL.gz	22283	Reanalyzed by: GSE205568	49	Pass	6-16-06	2	0	-26.8492848143997	P	100	1.18	N/A	N	IDC	RD	1/18	2	P	95	0	4	Taxol x 12 FAC x 4	W	2	2-2-07	TM/LNB	2
